

1 **Multi-omic association study identifies DNA methylation-mediated genotype and smoking**
2 **exposure effects on lung function in children living in urban settings**

3
4 Matthew Dapas¹, Emma E. Thompson¹, William Wentworth-Sheilds¹, Selene Clay¹, Cynthia M. Visness²,
5 Agustin Calatroni², Joanne E Sordillo³, Diane R. Gold^{4,5}, Robert A. Wood⁶, Melanie Makhija⁷, Gurjit K.
6 Khurana Hershey^{8,9}, Michael G. Sherenian^{8,9}, Rebecca S. Gruchalla¹⁰, Michelle A. Gill¹¹, Andrew H.
7 Liu¹², Haejin Kim¹³, Meyer Kattan¹⁴, Leonard B. Bacharier¹⁵, Deepa Rastogi¹⁶, Matthew C. Altman¹⁷,
8 William W. Busse¹⁸, Patrice M. Becker¹⁹, Dan Nicolae²⁰, George T. O'Connor²¹, James E. Gern¹⁸, Daniel
9 J. Jackson¹⁸, Carole Ober¹

10

11

12 ¹ Department of Human Genetics, University of Chicago, Chicago IL

13 ² Rho Inc., Durham, NC

14 ³ Department of Population Medicine, Harvard Medical School, Boston, MA

15 ⁴ Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA

16 ⁵ Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

17 ⁶ Department of Pediatrics, Johns Hopkins University Medical Center, Baltimore, MD

18 ⁷ Division of Allergy and Immunology, Ann & Robert H. Lurie Children's Hospital, Chicago, IL

19 ⁸ Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH

20 ⁹ Division of Asthma Research, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

21 ¹⁰ Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX

22 ¹¹ Department of Pediatrics, Washington University School of Medicine, St. Louis, MO

23 ¹² Department of Allergy and Immunology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora,

24 CO

25 ¹³ Department of Medicine, Henry Ford Health System, Detroit, MI

26 ¹⁴ Columbia University College of Physicians and Surgeons, New York, NY

27 ¹⁵ Monroe Carell Jr. Children's Hospital at Vanderbilt University Medical Center, Nashville, TN

28 ¹⁶ Children's National Health System, Washington, DC

29 ¹⁷ Department of Allergy and Infectious Diseases, University of Washington, Seattle, WA

30 ¹⁸ Department of Pediatrics and Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI

31 ¹⁹ National Institute of Allergy and Infectious Diseases, Bethesda, MD

32 ²⁰ Department of Statistics, University of Chicago, Chicago, IL

33 ²¹ Pulmonary Center, Boston University School of Medicine, Boston, MA

34 **ABSTRACT**

35 Impaired lung function in early life is associated with the subsequent development of chronic respiratory
36 disease. Most genetic associations with lung function have been identified in adults of European descent
37 and therefore may not represent those most relevant to pediatric populations and populations of different
38 ancestries. In this study, we performed genome-wide association analyses of lung function in a
39 multiethnic cohort of children (n=1035) living in low-income urban neighborhoods. We identified one
40 novel locus at the *TDRD9* gene in chromosome 14q32.33 associated with percent predicted forced
41 expiratory volume in one second (FEV₁) ($p=2.4 \times 10^{-9}$; $\beta_z = -0.31$, 95% CI= -0.41- -0.21). Mendelian
42 randomization and mediation analyses revealed that this genetic effect on FEV₁ was partially mediated by
43 DNA methylation levels at this locus in airway epithelial cells, which were also associated with
44 environmental tobacco smoke exposure ($p=0.015$). Promoter-enhancer interactions in airway epithelial
45 cells revealed chromatin interaction loops between FEV₁-associated variants in *TDRD9* and the promoter
46 region of the *PPP1R13B* gene, a stimulator of p53-mediated apoptosis. Expression of *PPP1R13B* in
47 airway epithelial cells was significantly associated the FEV₁ risk alleles ($p=1.26 \times 10^{-5}$; $\beta=0.12$, 95%
48 CI=0.06- 017). These combined results highlight a potential novel mechanism for reduced lung function
49 in urban youth resulting from both genetics and smoking exposure.

50 **AUTHOR SUMMARY**

51 Lung function is determined by both genetic and environmental factors. Impairment of lung function can
52 result from harmful environmental exposures in early life, which disproportionately affect children living
53 in low-income, urban communities. However, most genetic association studies of lung function have been
54 performed in adults and without regard for socioeconomic status. Therefore, genetic risk factors
55 discovered to date may not reflect those most relevant to high-risk populations. In this study, we sought to
56 identify genetic variants correlated with lung function in a multiethnic cohort of children living in low-
57 income, urban neighborhoods and analyze how tobacco smoke exposure may influence any genetic
58 effects. We discovered a common genetic variant associated with lower lung function in this population,
59 and we found that the association was mediated by nearby epigenetic changes in DNA methylation, which
60 were in turn correlated with smoking exposure. We then identified a nearby gene, *PPP1R13B*, which is
61 known to aid in the deactivation of damaged cells, whose expression in airway cells aligned with these
62 genetic and epigenetic effects. This study reveals a potential mechanism through which genetic risk and
63 environmental exposures can affect airway development, perhaps leading to interventions that can help
64 reduce the burden of asthma in socioeconomically disadvantaged children.

65 INTRODUCTION

66 Reduced lung function is a hallmark of asthma and chronic obstructive pulmonary disease (COPD). Lung
67 function measures, such as forced expiratory volume in one second (FEV₁) and forced vital capacity
68 (FVC), are strong predictors of future all-cause mortality [1-6]. Airway obstruction often begins in early
69 life [7-10], with lower lung function in infancy being a risk factor for the development of asthma in
70 childhood [11] and COPD in late adulthood [12].

71 Genetic factors contribute to differences in lung function among individuals, with heritability
72 estimates ranging from 0.50 for FEV₁ to 0.66 for FEV₁/FVC ratio [13]. The many genome-wide
73 association studies (GWAS) of lung function measures [14-25] have implicated pathways related to lung
74 development [20,26-28], inflammation [26], and tissue repair [29], among others [29]. Lung function is
75 also affected by environmental exposures, such as smoking [30-32] and air pollution [33], which can
76 disrupt airway development in early life, increasing the risk of childhood asthma and perhaps other
77 chronic obstructive diseases [8-12,34,35]. For example, exposure to second hand smoke in utero and
78 through childhood is associated with increased risk of childhood asthma [36], lower lung function in
79 adolescence [37], and larger declines in lung function later in life [38,39]. Such adverse exposures are
80 known to alter the epigenetic landscape in exposed individuals [40,41], potentially mediating downstream
81 biological effects [42-44] and modifying genetic associations with lung function [45,46].

82 Environmental risk factors disproportionately affect socioeconomically disadvantaged children,
83 particularly those living in urban environments [47,48]. In fact, socioeconomic effects contribute to
84 disparities in lung health [49], including the higher burden of chronic respiratory disease among Black
85 and Hispanic children compared to non-Hispanic white children [49-52]. Most genetic association studies
86 of lung function, however, have been limited to adults of European descent. Therefore, genetic risk
87 factors discovered to date may not reflect those most relevant to high-risk populations, which can further
88 exacerbate health disparities [53,54]. Identifying genetic variants and epigenetic variation associated with
89 lung function in high-risk, multiethnic, pediatric populations may provide more direct insights into the
90 early development of impaired lung function.

91 In this study, we analyzed measures of lung function from the Asthma Phenotypes in the Inner
92 City (APIC) [55,56] and Urban Environment and Childhood Asthma (URECA) cohorts [57], which
93 consist of children living in low-income neighborhoods in 10 U.S. cities. We performed whole-genome
94 sequencing (WGS) on 1,035 participants from APIC and URECA (ages 5-17 years; 67% non-Hispanic
95 Black, 25% Hispanic; 66% with doctor-diagnosed asthma) and performed a GWAS with FEV₁ and the
96 FEV₁/FVC ratio. We then performed expression quantitative trait locus (eQTL) and methylation
97 quantitative trait locus (meQTL) mapping in airway epithelial cells and peripheral blood mononuclear
98 cells (PBMCs) from a subset of the URECA children. We further tested for genotype and DNA
99 methylation interactions with smoking exposure. We aimed to identify methylation-mediated genetic and
100 smoking exposure associations with lung function, linking environmental effects, epigenetic
101 modifications, and specific genetic risk alleles to reduced pulmonary health in urban youth.

102

103

104 **RESULTS**

105 **Genetic variants at the *TDRD9* locus are associated with lung function**

106 We completed WGS and variant calling on 1,035 participants from the APIC and URECA studies
107 (APIC=508, URECA=527; **Table 1**). The mean sequencing depth was 31.6x per sample (**S1A Fig**). On
108 average, 95.3%, 90.3% and 62.6% of each genome was mapped with at least 10x, 20x and 30x
109 sequencing read depth, respectively (**S1B Fig**). Approximately 3.8 million high-confidence autosomal
110 variants were called per sample. Variant call concordance between replicate sample pairs (n=3) was
111 >99.9% for single nucleotide polymorphisms (SNPs) and was 98.9% for insertions and deletions (**S1**
112 **Table**).

113 **Table 1. Demographic characteristics of sequenced APIC and URECA participants.**

Characteristic	All	APIC	URECA
Number	1035	508	527
Age, years, mean (SD)	10.3 (2.5)	10.9 (3.1)	9.6 (1.1)
Female sex	477 (46%)	216 (43%)	261 (50%)
<i>Race/Ethnicity</i>			
Black (non-Hispanic)	696 (67%)	319 (63%)	377 (72%)
White (non-Hispanic)	14 (1%)	7 (1%)	7 (1%)
Hispanic	258 (25%)	153 (30%)	105 (20%)
Other/mixed	64 (6%)	26 (5%)	38 (7%)
Unknown	3 (<1%)	2 (<1%)	1 (<1%)
<i>Site</i>			
Baltimore	234 (23%)	85 (17%)	149 (28%)
Boston	189 (18%)	65 (13%)	124 (23%)
Chicago	62 (6%)	62 (12%)	-
Cincinnati	45 (4%)	45 (9%)	-
Dallas	38 (4%)	38 (9%)	-
Denver	59 (6%)	59 (12%)	-
Detroit	50 (5%)	50 (10%)	-
New York	164 (16%)	64 (13%)	100 (19%)
St. Louis	155 (15%)	-	155 (29%)
Washington, D.C.	39 (4%)	39 (8%)	-
Household income < \$15k	550 (54%)	273 (54%)	277 (54%)
Caretaker completed HS	756 (73%)	364 (72%)	392 (74%)
Caretaker smokes*	315 (33%)	123 (27%)	192 (39%)
Asthma	681 (75%)	508 (100%)	173 (43%)
BMI, Z-score, mean (SD)	0.9 (1.2)	1.0 (1.2)	0.8 (1.1)
FEV ₁ , % predicted, mean (SD)	94.9 (16.3)	91.9 (17.6)	98.5 (14.5)
FEV ₁ /FVC, mean (SD)	0.80 (0.09)	0.78 (0.10)	0.83 (0.07)

114 Results are presented as counts and percentages or as means with standard deviations. Missing data
 115 were not included in percentage calculations. Ages for URECA correspond to the year the genome-wide
 116 association study lung function data were collected. *Caretaker smoking status in URECA was collected
 117 at age 10. APIC: Asthma Phenotypes in the Inner City; BMI: body mass index; FEV₁: forced expiratory
 118 volume in one second; FEV₁/FVC: ratio of FEV₁ to forced vital capacity; HS: high school; URECA: Urban
 119 Environment and Childhood Asthma.

120

121 The sequenced cohort included 696 (67%) participants who self-identified as non-Hispanic Black

122 and 258 (25%) who self-identified as Hispanic (**Table 1**). Principal component and admixture analyses

123 using genotypes were used to characterize the ancestry of the participants (**Fig 1**). This revealed that the

124 genetic ancestry of our sample was 66% African, 26% European, 7% Native American, and 1% East
125 Asian. The cohort was 54% male and included 681 (66%) children diagnosed with asthma (**Table 1**).

126
127 **Fig 1. Ancestry composition of sequenced APIC & URECA participants.** A) The top two principal
128 components (PCs) of ancestry are plotted for sequenced APIC & URECA participants, colored by self-
129 identified race/ethnicity, along with the four ancestral reference populations used for determining
130 ancestry. NS= not specified. B) The proportion of genetic variance explained by each of the top 10 PCs.
131 C) The relative values of the top 10 PCs are plotted for each sample, colored by reference population. D)
132 The estimated proportion of admixture from each ancestral population is shown for each sequenced APIC
133 & URECA participant. Each vertical line corresponds to one sample. 1KG, 1000 Genomes project; HGDP,
134 Human Genome Diversity Project; YRI, Yoruba in Ibadan, Nigeria; CEU, Utah residents with Northern and
135 Western European ancestry; CHB, Han Chinese in Beijing, China; JPT, Japanese in Tokyo, Japan; NAT,
136 Native Americans from HGDP; EAS, East Asian ancestry; AFR, African ancestry; EUR, European
137 ancestry.
138

139 Using the WGS variant calls for 14.1 million variants with minor allele frequency (MAF) ≥ 0.01 ,
140 we performed a GWAS of two lung function traits: FEV₁ (% predicted) and FEV₁/FVC (Z-scores),
141 measured between ages 5-17 (**Table 1, S2 Fig**), adjusting for age, sex, asthma diagnosis, the first 10
142 principal components (PCs) of ancestry, and sample relatedness using a linear mixed model [58]. The
143 FEV₁ GWAS included 896 participants from APIC (n=504) and URECA (n=392), and the FEV₁/FVC
144 GWAS included 886 participants from APIC (n=497) and URECA (n=389). The genomic control factor,
145 λ_{GC} , for both GWAS results was 1.02 (**S3 Fig**), indicating adequate control for population stratification.
146 We identified one locus on chromosome 14q32.33 that was associated with FEV₁ at genome-wide
147 significance ($p < 2.5 \times 10^{-8}$); no other variants were associated with FEV₁ and no variants were associated
148 with FEV₁/FVC at genome-wide levels of significance (**Fig 2**). The FEV₁ locus on chromosome 14
149 consisted of a 200 kb region of associated variants in high linkage disequilibrium (LD) across the *TDRD9*
150 (Tudor Domain Containing 9) gene (**Fig 3, S2 Table**). The minor allele at the lead SNP (rs10220464;
151 MAF=0.30) was significantly associated with lower FEV₁ ($p = 2.4 \times 10^{-9}$; $\beta_z = -0.31$, 95% confidence
152 interval (CI)= -0.41- -0.21) and nominally associated with lower FEV₁/FVC ($p = 1.1 \times 10^{-3}$; $\beta_z = -0.17$, 95%
153 CI= -0.28- -0.07). Fine-mapping analysis at this locus (chr14:103.7-104.3Mb) revealed one 95% credible
154 set of effect variables consisting of 59 SNPs, with rs10220464 having the highest individual posterior

155 inclusion probability among them (**S4 Fig**). We did not detect any significant differences in rs10220464
156 association effect size by ancestry or asthma status or study for FEV₁ (**Fig 4**). Furthermore, the *TDRD9*
157 locus remained the only genome-wide significant association when the two GWAS were performed
158 without adjustment for asthma status (**S5 Fig**). The overall effect size correlations between asthma-
159 adjusted and unadjusted GWAS results were $r=0.981$ for FEV₁ and $r=0.954$ for FEV₁/FVC.

160
161 **Fig 2. Genome-wide association results.** GWAS Manhattan plots for **A**) FEV₁ and **B**) FEV₁/FVC ratio.
162 The horizontal red line indicates genome-wide significance ($p \leq 2.5 \times 10^{-8}$). The dotted horizontal blue line
163 indicates $p=1 \times 10^{-5}$. Variants colored in green are in previously identified GWAS loci [23]. FEV₁, forced
164 expiratory volume in one second; FEV₁/FVC, ratio of FEV₁ to forced vital capacity.

165
166
167 **Fig 3. FEV₁-associated variants on chromosome 14q32.33.** FEV₁ association results are shown at the
168 *TDRD9* gene locus. Each variant is plotted according to its position and $-\log_{10}$ p-value, colored by linkage
169 disequilibrium to the lead variant, rs10220464, within the sample. Candidate cis-Regulatory Elements
170 (cCREs) from ENCODE [59] are also shown for the region. The inset panel in the upper right shows the
171 distribution of adjusted FEV₁ values by rs10220464 genotype. FEV₁, forced expiratory volume in one
172 second; MAF, minor allele frequency; EnhD, distal enhancer-like signature; CTCF, CCCTC-binding factor
173 sites; enhP, proximal enhancer-like signature; prom, promoter-like signature; K4m3, trimethylation of
174 histone H3 at lysine 4.

175
176
177 **Fig 4. Rs10220464 effect size heterogeneity.** A forest plot of the associations between rs10220464 and
178 FEV₁ (% predicted) are shown for distinct sub-cohorts distinguished by self-identified race/ethnicity, study,
179 and asthma status. β_z , the association effect size between the rs10220464 allele count and the adjusted
180 and normalized FEV₁ (% predicted) values. FEV₁, forced expiratory volume in one second; N, total
181 number of individuals included in the association test; MAF, minor allele frequency within the sub-cohort;
182 P, the association p-value.

183
184 We examined association results for the previously identified FEV₁ and FEV₁/FVC loci reported
185 in the meta-analysis of the UK Biobank and SpiroMeta Consortium by Shrine and colleagues (n=400,102)
186 [23], which included 70 loci for FEV₁ and 117 for FEV₁/FVC. Of these, 64 of the lead SNPs for FEV₁
187 and 112 for FEV₁/FVC were genotyped in the APIC and URECA sample. Only one SNP, for FEV₁,
188 replicated with false discovery rate (FDR) $q < 0.05$ (rs9610955; $p=1.0 \times 10^{-4}$; $\beta_z = -0.38$, 95% CI= -0.58- -
189 0.19; **S6 Fig, S7 Fig**). Cumulatively, 56% (n=36) and 54% (n=60) of these SNPs demonstrated consistent
190 directions of effect for FEV₁ and FEV₁/FVC, respectively, with effect size correlations of 0.29 (95% CI=
191 0.05- 0.50; $p=0.020$) for FEV₁ and 0.42 (95% CI=0.25- 0.56; $p=4.2 \times 10^{-6}$) for FEV₁/FVC.

192

193 **Lung function risk alleles are associated with DNA methylation at the *TDRD9* locus in airway**

194 **epithelial cells**

195 The majority of complex trait-associated variants exert effects by altering gene regulatory networks [60-
196 62]. These changes are often marked by quantitative differences in DNA methylation levels [63-65]. We
197 therefore investigated correlations between the FEV₁-associated allele at *TDRD9* and DNA methylation at
198 the locus in upper airway (nasal) epithelial cells (NECs) from URECA children at age 11 (n=286). We
199 tested for associations between the FEV₁ genotype, as tagged by rs10220464, and DNA methylation
200 levels at 796 CpG sites within 10 kb of any *TDRD9* locus variants associated with FEV₁ at $p < 1 \times 10^{-5}$
201 (n=82 variants). The rs10220464 genotype was an meQTL for 5 CpG sites at an FDR <0.05 (**S3 Table**).
202 DNA methylation levels at only one of these CpG sites, cg03306306 ($p = 2.3 \times 10^{-4}$; $\beta = 0.07$, 95% CI=0.03-
203 0.10; **Fig 5a**), was also significantly associated with FEV₁ at age 10 in URECA ($p = 0.011$; $\beta = -11.48$, 95%
204 CI= -20.27- -2.69; **Fig 5b**). The rs10220464 genotype accounted for 4.7% of residual variation in
205 cg03306306 methylation, and cg03306306 methylation explained 2.4% of residual variation in FEV₁.

206

207 **Fig 5. Genotype and FEV₁ associations with DNA methylation.** DNA methylation levels at
208 cg03306306 are shown by rs10220464 genotype and FEV₁ measures are plotted against cg03306306
209 methylation levels in NECs at age 11 (A, B), and PBMCs at age 7 (C, D) from URECA. FEV₁, forced
210 expiratory volume in one second; NECs, nasal epithelial cells; PBMCs, peripheral blood mononuclear
211 cells; URECA, Urban Environment and Childhood Asthma study.

212

213 We then analyzed cg03306306 methylation in PBMCs collected at age 7 (n=169) [66] from
214 URECA children to evaluate whether the genotype and lung function associations observed in NECs were
215 shared with blood cells. In PBMCs, we observed no correlation between the rs10220464 risk allele and
216 cg03306306 methylation (**Fig 5c**), nor was there an association between cg03306306 methylation and
217 FEV₁ (**Fig 5d**). These results indicate that cg03306306 methylation dynamics in the airway epithelium are
218 not present in peripheral blood cells.

219

220 **Smoking exposure is associated with DNA methylation at the *TDRD9* locus**

221 DNA methylation at the *TDRD9* locus had previously been associated with maternal smoking during
222 pregnancy [67,68]. Therefore, we tested for associations between environmental tobacco smoke exposure
223 (**S8 Fig**) and DNA methylation at this locus in the URECA children. Methylation at cg03306306 in NECs
224 was significantly associated with nicotine metabolite (cotinine) levels in urine collected at ages 7-10 years
225 ($p=0.015$; $\beta=0.03$, 95% CI=0.01-0.05; **Fig 6**). Methylation at cg03306306 in PBMCs from age 7 was not
226 associated with urine cotinine levels.

227
228 **Fig 6. DNA methylation association with smoking exposure.** DNA methylation at cg03306306 in nasal
229 epithelial cells at age 11 are plotted against urine cotinine levels from URECA at ages 8-10 as measured
230 using the NicAlert assay ($n=285$). URECA, Urban Environment and Childhood Asthma study.
231

232 To determine if there was an interaction effect between genotype and smoking exposure on DNA
233 methylation and/or lung function, we repeated the cotinine association tests in URECA with the addition
234 of an interaction term to assess if the genotype effect differed between individuals with low and high
235 exposures to smoking. There were no significant genotype-by-smoking exposure interaction effects on
236 methylation levels in NECs or PBMCs in URECA, nor were there any significant methylation-by-
237 smoking effects on FEV_1 (**S9 Fig**). There was modest evidence for a genotype-by-smoking exposure
238 interaction effect on FEV_1 in the combined APIC and URECA sample, but this did not reach statistical
239 significance ($p=0.06$, **S10 Fig**). Considering the ages of the participants in APIC and URECA, most
240 tobacco exposures were likely due to secondhand smoke.

241

242 **Genetic effects on lung function are mediated by DNA methylation**

243 To determine if DNA methylation at the *TDRD9* locus had a causal effect on lung function, we performed
244 a Mendelian randomization analysis using two-stage least squares (2SLS) regression. In the first stage,
245 cg03306306 methylation levels in NECs were regressed on an instrument composed of four meQTLs for
246 cg03306306 (rs11160777, rs137961671, rs7143936, rs11160776; **Materials and Methods**). In the
247 second stage, FEV_1 was regressed on the predicted DNA methylation values generated from the first stage

248 regression, thereby yielding a causal effect estimate of cg03306306 methylation on FEV₁. Urine cotinine
249 levels were included as a covariate in both stages. The variance explained in the first stage regression was
250 $r^2=0.11$. The causal effect of cg03306306 methylation on FEV₁ was statistically significant ($p=0.020$). We
251 also tested a single, unweighted allele score of the instrumental variables and observed a causal effect
252 association of $p=0.045$ (stage-one $r^2=0.10$). We further performed a bootstrapped mediation analysis to
253 test whether the rs10220464 risk allele effect on FEV₁ was mediated by DNA methylation. The indirect
254 effect of rs10220464 on FEV₁ via cg03306306 methylation was significant, both when including asthma
255 as a covariate ($\beta_z=-0.04$, 95% CI=-0.10- -0.003, percent mediated=14.4%) and when asthma was not
256 considered ($\beta_z=-0.04$, 95% CI=-0.10- -0.002, percent mediated=15.0%). These results indicate that the
257 effect of the FEV₁-associated genotype at the *TDRD9* locus is partially mediated through its impact on
258 nearby DNA methylation levels.

259

260 **Gene expression and promoter-enhancer interactions implicate *PPP1R13B***

261 Trait-associated variants and DNA methylation often affect the transcriptome by influencing the
262 expression of one or more neighboring genes [69,70]. Identifying these correlations can help infer causal
263 mechanisms [71]. Therefore, we next explored the relationship between the genotype for the lead FEV₁
264 variant rs10220464 and the expression of genes within 1 Mb in NECs and PBMCs from URECA
265 children. Notably, the rs10220464 genotype was not associated with *TDRD9* expression levels in these
266 cells (NECs: $p=0.60$, $\beta=0.116$; PBMCs: $p=0.91$, $\beta=0.014$). Of the 27 genes that were evaluated (**S4**
267 **Table**), rs10220464 was significantly associated with the expression of only one gene, *PPP1R13B*
268 (Protein Phosphatase 1 Regulatory Subunit 13B; FDR $q=2.77 \times 10^{-4}$; $p=1.26 \times 10^{-5}$; $\beta=0.12$, 95% CI=0.06-
269 017; **Fig 7a**), in NECs. *PPP1R13B* expression levels were also the most strongly associated of the 27
270 genes with methylation at cg03306306 in NECs ($p=0.018$; $\beta=0.10$, 95% CI=0.02- 018; **Fig 7b**).

271 *PPP1R13B* expression in NECs, however, was not associated with FEV₁ or smoking exposure (**S11 Fig**).

272

273 **Fig 7. *PPP1R13B* gene expression in NECs.** *PPP1R13B* gene expression in NECs at age 11 are
274 plotted against A) rs10220464 genotype (n=324) and B) DNA methylation at cg03306306 in NECs at age
275 11 (n=254). NECs, nasal epithelial cells; CPM, counts per million.
276

277 The transcription start site of *PPP1R13B* resides 87 kb from rs10220464 and 152 kb from
278 cg03306306, suggesting long-range interactions between the FEV₁-associated genotype and the promoter
279 of *PPP1R13B*. To determine whether any of the FEV₁-associated GWAS variants at the *TDRD9* locus
280 resided in regions that physically interacted with the promoters of *cis*-genes, we evaluated chromatin
281 interactions in lower airway (bronchial) epithelial cells (BECs) [72], assessed by promoter-capture Hi-C.
282 Forty-two of the GWAS variants resided in regions that interacted with the promoters of 9 different genes
283 expressed in NECs (**Fig 8; S5 Table**). The gene most frequently mapped to these variants was
284 *PPP1R13B*, with 15 variants located in 3 different interaction loops. Moreover, the strongest observed
285 interaction was between a region containing 4 FEV₁-associated variants and the *PPP1R13B* promoter
286 (CHiCAGO score = 9.38; **S5 Table**), suggesting that this region is an enhancer for *PPP1R13B*
287 expression. This putative enhancer region is located just 2.21 kb from cg03306306.

288
289 **Fig 8. Promoter-enhancer interactions at *TDRD9* locus in nasal epithelial cells.** Promoter-to-
290 enhancer chromatin interactions captured by Hi-C in nasal epithelial cells from URECA at age 11 are
291 displayed as grey arcs. SNPs associated with FEV₁ ($p < 1 \times 10^{-5}$) are marked by blue lines in the top row
292 according to their genomic position on chromosome 14. The lead FEV₁ SNP, rs1022464, is highlighted in
293 yellow. CpG sites associated with rs1022464 (FDR < 0.05) are displayed as green markers below the
294 genes, with cg03306306 highlighted in green. Chromatin Interactions containing SNPs associated with
295 FEV₁ ($p < 1 \times 10^{-5}$) are highlighted in blue. Magenta arcs highlight interactions between the *PPP1R13B*
296 promoter and regions containing FEV₁ SNPs and/or rs1022464-associated CpG sites. FEV₁, forced
297 expiratory volume in one second; SNPs, single nucleotide polymorphisms; meQTL, methylation
298 quantitative trait locus; pHi-C, promoter capture Hi-C.
299

300

301 **Summary of study associations**

302 The associations between the *TDRD9* risk allele, cg03306306 DNA methylation in NECs, smoking
303 exposure, *PPP1R13B* gene expression, and FEV₁ (% predicted) reported in this study are summarized in

304 **Fig 9.**

305
306 **Fig 9. Summary of study associations.** The *TDRD9* locus was significantly associated with FEV₁ (%
307 predicted) in the APIC and URECA cohorts. This association was partially mediated by DNA methylation
308 at the cg03306306 CpG site in *TDRD9* in NECs, which was also significantly associated with
309 environmental tobacco smoke exposure. The *TDRD9* risk allele and DNA methylation were both
310 significantly associated with *PPP1R13B* gene expression, but *PPP1R13B* gene expression was not
311 significantly correlated with FEV₁ itself. Unidirectional arrows represent inferred causality.

312
313

314

315 **DISCUSSION**

316 Using whole-genome sequence variant calls in an asthma-enriched cohort of predominantly African-
317 American children raised in urban environments, we identified a genotype at the *TDRD9* locus associated
318 with lower FEV₁ % predicted. This genotype effect was partially mediated by DNA methylation in airway
319 epithelial cells, which were also correlated with smoking exposure. Data from RNA-sequencing and
320 promoter-capture Hi-C in airway epithelial cells suggested that these FEV₁-associated genetic and
321 epigenetic variations influence the expression of the *PPP1R13B* gene through long-range interactions.

322 The *PPP1R13B* gene encodes a protein that promotes apoptosis, a form of programmed cell
323 death, via its interaction with the tumor suppressor p53 and is often referred to by its alias ASPP1
324 (apoptosis-stimulating protein of p53 1) [73]. In response to oncogenic stress, PPP1R13B translocates to
325 the nucleus, where it enhances the transcriptional activity of p53 on specific target genes relevant to
326 apoptosis [74,75]. Exposure to smoking and fine particulate matter induces epithelial apoptosis in the
327 lung via p53 [76-78]. PPP1R13B may also promote apoptosis in a p53-independent manner by inhibiting
328 autophagy in response to upregulation by EGR-1 (early growth response protein 1) [79]. EGR-1 mediates
329 stress-induced proinflammatory responses in the airway epithelium and contributes to the pathogenesis of
330 COPD [80-85]. Within the lung, *PPP1R13B* is indeed predominantly expressed in epithelial cells,
331 particularly in alveolar type 2 cells, and less so in immune cells and fibroblasts [86,87]. However, Cheng
332 and colleagues studied PPP1R13B function in lung fibroblasts and found that it was upregulated
333 following SiO₂ exposure, where it promoted fibroblast proliferation and migration through endoplasmic
334 reticulum stress and autophagy pathways [88]. Overall, these studies suggest that *PPP1R13B* plays a key

335 role in maintaining tissue homeostasis by regulating apoptosis and autophagy in response to
336 environmental stimuli [74,89,90]. The specific function(s) of this gene in the airway epithelium and its
337 potential impact on the development of airway obstruction remain to be elucidated. *PPP1R13B*
338 expression in airway epithelial cells at age 11 was not directly associated with lung function or urine
339 cotinine levels in the URECA children, but the cofactors of this gene [79,91] have been found previously
340 to be upregulated in smokers with COPD [81,92]. Given its association with lung function alleles in our
341 study, its expression in the airway epithelium, and its purported functions in autophagy and apoptosis
342 pathways, additional study of *PPP1R13B* in lung and airway development is warranted, particularly in the
343 context of adverse environmental stimuli, many of which are enriched in low-income urban
344 environments.

345 In NECs, *PPP1R13B* gene expression was significantly associated with DNA methylation levels
346 at the cg03306306 CpG site in *TDRD9*. Methylation at the *TDRD9* locus was previously reported to
347 correlate with specific environmental exposures [67,68,93] and with *TDRD9* expression in blood [67,94].
348 *TDRD9* is lowly expressed in the lung but is detected in alveolar macrophages and in monocytes [86,87].
349 Interestingly, the gene was among the most differentially expressed genes in alveolar macrophages in
350 smokers relative to non-smokers [95], and its knockdown in *TDRD9*-expressing lung carcinomas resulted
351 in increased apoptosis [96]. Its expression was not correlated with the rs10220464 genotype in URECA
352 NECs or PBMCs, but rs10220464 is an eQTL for *TDRD9* expression in whole blood in GTEx data [97],
353 with the minor allele associated with lower *TDRD9* expression. Although evidence from this study points
354 to *PPP1R13B* in the airway epithelium, we can't exclude the possibility that *TDRD9* or other genes could
355 contribute to the locus' influence on lung function via other tissues.

356 The correlations of FEV₁ and rs10220464 with cg03306306 methylation and *PPP1R13B*
357 expression in NECs were absent in PBMCs. Although global DNA methylation patterns between tissues
358 are highly correlated [98], tissue-specific differentially methylated regions are more likely to be
359 functional, particularly if they are positively correlated with gene expression [99]. The *TDRD9* locus has
360 not been identified in epigenome-wide association studies of lung function [44,100-104], but these

361 measured DNA methylation from blood, which may be an insufficient proxy for methylation in the lungs
362 [105]. Indeed, previous studies have found that DNA methylation profiles in NECs are significantly more
363 predictive of pediatric asthma than those in PBMCs [106,107]. Furthermore, epigenetic biomarkers can
364 change with age. For example, epigenetic markers for lung function in adults do not replicate in children
365 [101].

366 The FEV₁ association signal at the *TDRD9* locus included many variants in high LD across a 200
367 kb region that could be independently contributing to function. Some of the variants lie in different long-
368 range enhancers [59]. It is also possible that one or more correlated variants were not included because
369 they failed quality control standards. In addition, due to the limited sample size of the WGS cohort, we
370 excluded rare variants (MAF<0.01) from consideration, which could contribute to the signal at this locus.
371 Additional functional studies are needed to identify the causal variant(s) and full mechanism of action.

372 If increased methylation at cg03306306 leads to lower FEV₁ in response to environmental
373 stressors, one might expect to see interaction effects with smoking exposure on FEV₁. We did not detect
374 any such interactions, although our analyses in that regard were likely underpowered given our observed
375 effects and sample sizes [36]. Furthermore, because this study was limited to children living in low-
376 income urban neighborhoods, environmental risk factors are likely to be more prevalent than in the
377 general population [55-57]. Additionally, such exposures are not necessarily ubiquitous across all the
378 different neighborhoods and communities represented in this sample, and although environmental tobacco
379 smoke exposure was examined and the socioeconomic range represented in this study is relatively
380 narrow, there could be relevant environmental factors that were not considered.

381 To infer causality, Mendelian randomization and mediation analyses rely on assumptions that are
382 often difficult to empirically verify. For the Mendelian randomization analysis, we identified instrumental
383 variants associated with the intermediate cg03306306 that were not independently associated with the
384 outcome, FEV₁. However, because these variants were selected from the same dataset that the outcome
385 testing was performed in, they were susceptible to bias from winner's curse [108]. To mitigate the
386 potential impact from this effect and from weak instruments, we performed a secondary analysis in which

387 we combined the instrumental variants into a single, unweighted score. For the mediation analysis,
388 unmeasured confounding can invalidate direct and indirect effect estimates [109]. To protect against such
389 bias, we systematically tested for confounding associations with additional environmental measures
390 available in APIC and URECA (**Materials and Methods**). Nonetheless, there may still exist unknown
391 confounding factors that were not measured. Ultimately the results of the Mendelian randomization and
392 mediation analyses indicate that methylation at cg03306306 in NECs mediated the rs10220464 genotype
393 effect on FEV₁, but there was residual correlation between rs10220464 and FEV₁, signifying that the
394 genotype effect was only partially mediated by cg03306306.

395 Another limitation of our study was the relatively small size for a GWAS. This likely contributed
396 to the lack of statistically significant replication for previously identified lung function loci [23],
397 considering that the observed effects were correlated with results of prior GWAS. However, the APIC
398 and URECA cohorts represent understudied, high-risk, pediatric populations that likely harbor distinct
399 genetic and environmental risk factors compared to older, primarily European ancestry cohorts included
400 in previous GWAS of lung function [14-20,23]. The findings of this study have yet to be replicated in an
401 independent cohort, and should therefore be considered preliminary; however, it is possible that these
402 associations would differ in populations with dissimilar ancestry, age, exposures, and/or asthma risk.

403 There are additional caveats to consider when interpreting our findings. First, this study
404 integrated data from two cohorts with different recruitment criteria, asthma definitions, and ancestral
405 compositions. Furthermore, most of the analyses beyond the GWAS were limited to subsets of the
406 URECA participants. However, we did not observe significant genetic effect heterogeneity for
407 rs10220464 by study, asthma status, or ancestry. To control for potential population stratification, we
408 used the first ten PCs of ancestry to adjust lung function values and then included the ancestry PCs as
409 fixed effects in the GWAS models (**Materials and Methods**). The linear mixed models also included a
410 genetic relatedness matrix as a random effect to account for residual population structure. Because
411 children with asthma have lower lung function overall (**Table 1**) and their lung function may be more
412 affected by environmental exposures [110-112], we adjusted for asthma status in the GWAS, as in

413 previous GWAS [113-116]. The likelihood of discovering lung function variants with consistent effects in
414 asthmatics and non-asthmatics was thereby increased, although genetic determinants of lung function may
415 differ by asthma status [117]. Furthermore, adjusting for disease status could potentially introduce
416 collider bias [118]. The significant genotype effect at the *TDRD9* locus, however, remained the only
417 genome-wide-significant association when asthma was excluded as a covariate, and adjustment for
418 asthma did not substantively alter the mediation results. Second, some of the analyses used data collected
419 at different timepoints. For example, most of the urine cotinine and spirometry measures were collected at
420 age 10, but the samples used for the NEC DNA methylation and RNA-seq analyses were collected at age
421 11. Because DNA methylation and gene expression can change over time [40,119-121], their values at
422 age 11 may not be fully representative of exposures at age 10. Finally, the promoter-capture Hi-C data
423 were from lower airway (bronchial) epithelial cells, whereas the DNA methylation and RNA-seq data
424 were generated from upper airway (nasal) epithelial cells. Although there are transcriptomic differences
425 between epithelial cells from each compartment, their respective profiles are highly correlated [122-126],
426 and the use of NECs as a proxy for the lower airway epithelium has been validated for both gene
427 expression and epigenetic studies [124-127].

428 Our study identified a novel avenue through which genetic risk and environmental exposures
429 could affect the airways of children raised in low-income urban neighborhoods. Further research into this
430 pathway may yield mechanistic insights into the early development of impaired lung function, perhaps
431 leading to interventions that can help reduce the high incidence and morbidity of chronic respiratory
432 diseases in socioeconomically disadvantaged children.

433

434 **MATERIALS AND METHODS**

435 **Study Population and Phenotypes**

436 We analyzed samples and phenotypes from two National Institutes of Allergy and Infectious
437 Diseases (NIAID)-funded asthma studies conducted by the Inner-City Asthma Consortium (ICAC)[128]:
438 the Asthma Phenotypes in the Inner City (APIC) study[55,56] and the Urban Environment and Childhood
439 Asthma (URECA) birth cohort study [57]. The APIC study was a 1-year, prospective, epidemiological
440 investigation of children and adolescents with asthma (ages 6-17) living in low-income areas ($\geq 20\%$ of
441 residents below poverty level) in nine U.S. cities (Baltimore, MD; Boston, MA; Chicago, IL; Cincinnati,
442 OH; Dallas, TX; Denver, CO; Detroit, MI; New York, NY; Washington, DC). The APIC participants
443 were required to have a diagnosis of asthma by a physician and to have had at least two episodes
444 requiring bronchodilator administration within the past year [55]. The URECA study enrolled pregnant
445 women living in low-income areas of four U.S. cities (Baltimore, MD; Boston, MA; New York, NY; St.
446 Louis, MO) who reported that either or both parents of the index pregnancy had a history of asthma or
447 allergic diseases [57]. This prospective, longitudinal study followed each child through adolescence,
448 periodically collecting samples and clinical and environmental exposure data. Institutional review board
449 approval was received from all participating sites, and written informed consent was obtained from legal
450 guardians of all participating children, who also assented.

451 Lung function was assessed using spirometry. Lung function measures used in this study for
452 APIC participants were taken at the study entry visit (V0). For URECA, measurements from age 10 were
453 used when available; otherwise, the most recent measurement after age 5 was used (**S6 Table**). Asthma
454 status was assigned according to study-specific criteria. For APIC, asthma was defined by a doctor's
455 diagnosis of asthma and short-acting beta-agonist use in the year prior [55]. For URECA, asthma status
456 was determined either by doctor diagnosis, lung function reversibility, or symptom recurrence [129]. The
457 2012 Global Lung Initiative reference equations [130] were applied to generate percent predicted
458 estimates for FEV₁ and Z-scores for FEV₁/FVC ratio. Urine cotinine levels were measured using NicAlert
459 immunochromatographic assays, which report results on a scale of 0-6 according to different cotinine

460 concentration ranges [131]. For URECA, urine cotinine results were available at age 10 for most
461 participants (n=391); otherwise, assays from age 8 (n=29) or age 7 (n=2) were used. This study utilized
462 DNA methylation and RNA-seq data generated for other URECA studies; therefore, the number of
463 samples included in each analysis varied and was limited by data availability (**S7 Table, S12 Fig**).

464

465 **Whole-Genome Sequencing and Data Processing**

466 DNA was extracted from peripheral blood (APIC, URECA) or cord blood (URECA) and quantified using
467 an Invitrogen Qubit 3 Fluorometer. DNA quality was assessed using the Thermo Scientific NanoDrop
468 One spectrophotometer and confirmed using an Agilent TapeStation system. DNA was processed in
469 batches of 60 using the Illumina Nextera DNA Flex library prep kit with unique dual adaptors. Each set of
470 60 libraries was sequenced over two NovaSEQ S4 flowcells. Whole-genome sequencing was performed
471 by the University of Chicago Genomics Facility using the Illumina NovaSEQ6000, which generated 150
472 bp paired-end reads. Sequencing data processing followed the Broad Institute's Genome Analysis Toolkit
473 (GATK) best practices for germline short variant discovery, as implemented in the harmonized pipeline
474 used by the New York Genome Center for TOPMed [132,133]. Reads were aligned to the GRCh38
475 human reference genome (including alternate loci and decoy contigs) using BWA-MEM (Burrows-
476 Wheeler Aligner; v0.7.17). Aligned reads further underwent duplicate removal (Picard MarkDuplicates;
477 v2.8.1) and base quality score recalibration (GATK BaseRecalibrator; v3.8) against known sites
478 (dbSNP138, known indels, and Mills and 1KG gold standard indels) provided in the GATK resource
479 bundle. Read alignment metrics were calculated using Picard CollectWgsMetrics (v2.8.1) for all aligned
480 reads and for aligned reads with base quality and mapping quality ≥ 20 . DNA contamination levels were
481 estimated using VerifyBamID2 (v1.0.6) [134]. Samples with estimated DNA contamination >0.05 were
482 removed from consideration. Samples with poor coverage ($<50\%$ of the genome with $\geq 20x$ depth) were
483 also removed from further consideration. To identify potential sample swaps, WGS samples were
484 validated using independent genotyping arrays.

485

486 **QC Array for Sample Validation**

487 To identify potential WGS sample swaps, we independently genotyped the APIC and URECA
488 participants using the Illumina QC Array-24 BeadChip. SNPs were tested for Hardy-Weinberg
489 Equilibrium (HWE) within each self-identified ancestry group using the chi-square test and removed if
490 they deviated from HWE (Bonferroni-adjusted $p < 0.05$) within at least one ancestry. SNPs with call rates
491 < 0.98 were also removed. Samples with total variant call rates < 0.95 were not used. Array data with
492 incorrect or indeterminate sex according to X-chromosome heterozygosity rates (Plink v1.90) were also
493 not used [135]. For fourteen of the sequenced URECA samples, we used results from the Illumina
494 Infinium CoreExome+Custom array for sample validation, which were generated and controlled for
495 quality as described by McKennan and colleagues [136]. WGS and array genotypes were tested for
496 concordance using VerifyBamID (v1.1.3) [137]. WGS samples that were not validated with array data
497 were not included in genetic analyses ($n=2$).

498

499 **Variant Calling and Quality Control**

500 Variant calls were generated using GATK HaplotypeCaller (v4.1.3.0), accounting for contamination
501 estimates, for single nucleotide variants and short insertions, deletions, and substitutions. Sample
502 genotypes were joined using GATK GenomicsDBImport and GenotypeGVCFs over the genomic
503 intervals defined in the GATK WGS calling region interval list provided in the GATK resource bundle.
504 Genotypes with read depth (DP) < 10 or quality scores (GQ) < 20 were set as missing. Sites with ≥ 0.1
505 missingness were then removed from consideration. Variants with minor allele frequencies > 0.05 were
506 tested for accordance with HWE, accounting for population structure [138]. Sites with common variants
507 that deviated from structural HWE ($P < 1 \times 10^{-6}$) were removed from consideration. Sites with quality by
508 depth ratios (QD) < 4 or > 34 were also removed, as we observed declines in variant transition/transversion
509 (TS/TV) ratios beyond these bounds (**S13 Fig**). Variant site quality was further evaluated using machine-
510 learning-based Variant Quality Score Recalibration (VQSR). First, SNPs were modeled using GATK
511 VariantRecalibrator (v4.1.3.0) with Hapmap 3 and with Omni 2.5M SNP chip array as truth resources,

512 1000G as a training resource, and dbSNP138 as a known sites resource. InDels were likewise trained with
513 the Mills and 1KG gold standard indels dataset as a truth resource and dbSNP138 as a known sites
514 resource. SNPs and InDels with resultant predicted true positive probabilities below 0.997 and 0.990,
515 respectively, were removed from consideration. Variant call accuracy was assessed by comparing call
516 concordance between three replicate sequencing samples using VCFtools (v0.1.14) vcf-compare [139].
517 Variant call file manipulation was conducted using BCFtools (v1.10.2) [140].

518

519 **Ancestry Estimation**

520 Ancestry principal components (PCs) were calculated on the intersect of high quality single-nucleotide
521 variants (SNVs) genotyped in the WGS data and several reference panels from the 1000 Genomes Project
522 (1KG; n=156) [141] and the Human Genome Diversity Project (HGDP; n=52) [142]. Native American
523 reference samples consisted of 52 samples from the HGDP with <5% non-native ancestry, according to
524 an analysis of roughly 2 million markers using the program ADMIXTURE (v1.3.0) [143]. These samples
525 were filtered for site quality (missingness 5%; ExcHet<60; VQSLOD \geq 8.3929), genotype quality
526 (GQ \geq 20) and depth (DP \geq 10), MAF >0.02, and HWE (p>0.001) [142]. European, West African, and East
527 Asian reference samples were randomly selected from CEU (n=52), YRI (n=52), JPT (n=26), and CHB
528 (n=26) samples in the phase 3 1KG reference panel [141]. The combined genotypes were pruned for
529 linkage disequilibrium (LD) \leq 0.1 within 1Mb intervals. Ancestry PCs were calculated, accounting for
530 subject relatedness, using PC-Air [144] and PC-Relate [145]. Initial kinship estimates were produced
531 using KING[146]. Kinship and PCs were iteratively estimated using PC-Relate and PC-Air, respectively,
532 until estimates for the top 5 PCs stabilized (n=3). Reference population admixture estimates were
533 estimated for each WGS sample with ADMIXTURE (v1.3.0), using the 1KG and HGDP reference
534 samples for supervised analysis [143]. Because sample relatedness can lead to biased admixture estimates
535 [144,147], admixture was estimated for each WGS sample separately.

536

537 **Quantitative Trait Association Testing**

538 Quantitative traits were adjusted for covariates and normalized using a two-stage approach [148,149].
539 First, each trait was regressed on age, sex, asthma status, and the first 10 PCs of ancestry. The residuals
540 were then rank-normalized using an inverse normal transformation. In the second stage, the normalized
541 residuals were considered outcome variables in the GWAS, adjusting for the same covariates as in the
542 first stage. Genome-wide association testing was performed for all high-quality common variant calls
543 ($MAF \geq 0.01$) using a linear mixed model, as implemented in GEMMA [58], with subject relatedness
544 included as a random effect. Individuals who were not evaluated for asthma at ages 7 or 10 ($n=127$) were
545 excluded from trait association testing. The threshold we applied for genome-wide significance was
546 $P \leq 2.5 \times 10^{-8}$, based on a 5×10^{-8} GWAS threshold and further accounting for two tests. To identify potential
547 collider bias introduced by adjusting for asthma status, we repeated the GWAS without accounting for
548 asthma status in either covariate-adjustment stage.

549 Fine-mapping analysis was conducted using SuSiE (SusieR R package v0.12.27) [150]. SuSiE
550 applies a form of Bayesian variable selection in regression using iterative Bayesian stepwise selection to
551 identify “credible sets” of variables. Each credible set has a 95% probability of containing at least one
552 causal effect SNP. Prior to running SuSiE, we regressed asthma, age, sex, and ancestry PCs 1-10 from the
553 genotype matrix and outcome vector (the normalized FEV_1 residuals).

554 To explore whether there was lead-SNP effect heterogeneity by ancestry, study, or asthma status,
555 we performed additional single-SNP quantitative trait association tests within several different sub-
556 cohorts and introduced interaction effects into our models. For ancestry, we performed separate
557 association tests in each of the Black, Hispanic, and white populations, according to self-identified
558 race/ethnicity. We then tested for genotype-by-ancestry interaction effects across APIC and URECA by
559 using admixture proportions as covariates in our models, in lieu of ancestry PCs, and including an
560 interaction term with the lead SNP for each continental ancestry group in turn. We tested these interaction
561 effects using the `--gxe` argument in GEMMA in four separate models (one for each ancestry). To
562 determine whether there was effect heterogeneity by study (APIC vs. URECA), we performed separate
563 association tests in each study and also tested the association across APIC and URECA with the addition

564 of a study covariate and a genotype-by-study interaction term. For asthma status, we performed separate
565 association tests in the asthmatics and non-asthmatics and tested a genotype interaction term with asthma
566 status.

567

568 **DNA Methylation Analysis**

569 DNA from NECs was collected at age 11 from 287 URECA participants and assessed for genome-wide
570 methylation patterns using the Illumina Infinium Human Methylation EPIC Beadchip. DNA methylation
571 levels from PBMCs at age 7 in URECA were collected and processed as previously described [66].
572 MeQTL analysis was performed using Matrix eQTL [151]. NEC DNA methylation levels were adjusted
573 globally for sex, array, plate, collection site, DNA concentration, percent ciliated epithelial cells, percent
574 squamous cells, and ancestry PCs 1-3. Principal components analysis was then performed on the residual
575 methylation levels, and the first three PCs were included as covariates in the meQTL association
576 tests. Additional methylation PCs were not included in association tests, as they were significantly
577 correlated with asthma phenotypes. Associations with FDR-adjusted $P < 0.05$ were considered significant.
578 MeQTL analysis with the PBMC data included sex, collection site, plate, ancestry PCs 1-3, and eight
579 latent factors [152] (protecting for FEV₁ at age 7) as covariates.

580 To test CpG site methylation associations with lung function in NECs, we performed linear
581 regressions on the most recent FEV₁ measures, with age, sex, ancestry PCs 1-3, and methylation PCs 1-3
582 as covariates. For the PBMC analysis, we set FEV₁ at age 7 as the dependent variable, with sex, collection
583 site, plate, ancestry PCs 1-3, and latent factors included as covariates.

584 For association testing with smoking exposures, we ran linear regressions for DNA methylation
585 and lung function in NECs and PBMCs, as described above, with the addition of cotinine concentrations
586 as a predictor. We further tested for smoking-by-genotype interaction effects on DNA methylation and
587 lung function using these models by adding an interaction term (cotinine concentration : rs10220464
588 genotype). Proportions of explained variance were calculated by squaring partial correlation coefficients

589 of regression model predictors [153]. One sample from one sibling pair was removed from all methylation
590 analyses to prevent confounding due to relatedness.

591

592 **Mendelian Randomization and Mediation Analysis**

593 To assess the causal effects of DNA methylation on lung function, we performed one-sample Mendelian
594 randomization analysis. We applied a 2SLS regression to URECA samples with WGS and DNA
595 methylation data (n=285) using ivreg [154]. DNA methylation levels in NECs at the cg03306306 CpG
596 site were first adjusted for methylation PCs 1-3 and used as the endogenous, exposure variable. The
597 adjusted and normalized FEV₁ values from the GWAS were set as the dependent outcome variable. Urine
598 cotinine levels were included as an exogenous covariate (included in both stages). The instrumental
599 variables were chosen from a set of candidate SNPs that were at least nominally associated with
600 cg03306306 methylation with p<0.15. Clustering of pairwise linkage disequilibrium values between these
601 SNPs revealed six distinct haplotypes (S14 Fig). To ensure instrument exogeneity, each candidate SNP
602 was tested for association with FEV₁ after conditioning on cg03306306 methylation and urine cotinine,
603 and SNPs associated with p<0.05 were removed from consideration. Of the remaining candidate SNPs,
604 one was chosen from each haplotype, resulting in an instrument composed of 4 SNPs (rs11160777,
605 rs137961671, rs7143936, rs11160776). Instrument relevance was validated using the F test, endogeneity
606 using the Wu-Hausman test, and instrument exogeneity using the Sargon test. We tested two 2SLS
607 models: one where the instrumental variables were included as individual predictors, and another
608 featuring an unweighted allele score of the four instrumental variants to reduce potential bias from weak
609 instruments and/or winner's curse [155,156].

610 Mediation analysis was conducted with ROBMED [157]. The adjusted and normalized FEV₁
611 residuals were set as the dependent variable, adjusted cg03306306 methylation as the mediator, and
612 rs10220464 as the independent variable. Age at FEV₁ measurement, sex, asthma status, ancestry PCs 1-3,
613 and urine cotinine levels were included as covariates. We also performed a secondary mediation analysis
614 without adjusting for asthma status. To identify additional, potential confounders that could invalidate our

615 mediation model, we systematically tested for associations with 2 socioeconomic variables and 11
616 environmental exposures available in APIC and URECA (**S8 Table, S15 Fig**). For each environmental
617 exposure, we tested whether the variable was associated with the mediator (cg03306306) and whether the
618 variable was associated with the outcome (FEV₁) conditional on the mediator. To ensure no exposure-
619 mediator interactions, we repeated the cg03306306 association test with FEV₁ with rs10220464 included
620 as a predictor with a rs10220464: cg03306306 interaction term. The indirect effect of rs10220464 on
621 FEV₁ via cg03306306 methylation was estimated using 100,000 bootstrap resamples.

622

623 **Gene Expression Analysis**

624 We analyzed gene expression in NECs and PBMCs from the URECA birth cohort using RNA-seq. The
625 NEC data were derived from 323 children (155 females, 168 males) at age 11 years at the time of sample
626 collection, and the PBMC data were derived from 130 (53 females, 77 males) PBMC children aged 2
627 years at the time of collection. Sequencing reads were mapped and quantified using STAR (v2.6.1) [158]
628 and samples underwent trimmed means of M-value (TMM) normalization and voom transformation
629 [159]. Genes with <1 count per million mapped reads (CPM) were removed from analysis. For eQTL
630 association testing in NECs we corrected for sex, the first three ancestral PCs, collection site, epithelial
631 cell proportion, sequencing batch, and 14 latent factors [152] using limma [160]. In PBMCs, we corrected
632 for sex, the first three ancestral PCs, collection site, and 19 latent factors.

633

634 **Chromatin Interaction Analysis**

635 Chromatin interactions were assessed using promoter capture Hi-C [161,162] in ex vivo human BECs
636 from 8 adult lung donors, including 4 with asthma. The data was processed and analyzed as previously
637 described [72,163]. Chromosomal interactions were evaluated using the CHiCAGO algorithm [164].
638 Interactions with CHiCAGO scores ≥ 5 were considered significant [164]. Genetic variants within 1 kb of
639 a given interacting fragment were considered part of the chromatin loop. Genes that were not expressed in
640 NECs were not included in the analysis.

641 **DATA AVAILABILITY**

642 Phenotype, genotype, GWAS summary statistics, and whole-genome sequencing files are available in
643 dbGaP under accession **phs002921.v1.p1**. The URECA gene expression data are available on the Gene
644 Expression Omnibus (GEO) under the accession **GSE145505** (NECs) and **GSE96783** (PBMCs). The
645 pcHi-C data are available in GEO under the reference series **GSE152550**. The DNA methylation data will
646 be deposited to GEO (Morin, et al. A Functional Genomics Pipeline to Identify High-Value Asthma and
647 Allergy CpGs in the Human Methylome. medRxiv. 2022:2022.05.19.22275204).

648

649 **ACKNOWLEDGEMENTS**

650 We are grateful to all participants and their families who took part in these studies. We would like to
651 extend special thanks to Pieter Faber and the University of Chicago Genomics Facility, as well as to Petra
652 LeBeau and Rebecca Z. Krouse, formerly of Rho Inc., for their respective contributions.

653

654 **FUNDING**

655 This work was supported by NIH grants U19 AI62310, HHSN272200900052C, HHSN272201000052I,
656 UM1 AI114271, UG3 OD023282, and UM1 AI160040. Site data collection was supported by the
657 following NIH grants: RR00052, UL1 TR001079 (Baltimore); M01 RR00533, UL1 RR025771, 1 UL1
658 TR001430 (Boston); UL1 TR000150 (Chicago); UL1 TR000451, UL1 TR001105 (Dallas); U11
659 RR025780 (Denver); UL1 TR000040, M01 RR00071, UL1 RR024156 (New York); UL1 TR000075
660 (D.C.); UL1 TR000077 (Cincinnati). M.D. was supported by TL1 TR002388 and T32 HL007605.

661

662 **AUTHOR CONTRIBUTIONS**

663 M.D., W.W.B., P.B., D.N., G.T.O., J.E.G., D.J.J., C.O. made contributions to the conception and/or
664 design of the study. M.D., E.T., and S.C. performed computational analyses. E.T. prepared samples for
665 ‘omic analyses. W.W.S. oversaw ‘omic data management. C.M.V. and A.C. oversaw clinical data
666 management. J.E.S., D.G., G.T.O., J.E.G., D.J.J., C.O. contributed to interpretation of results. R.A.W.,

667 M.M., G.N.K.H., M.G.S., R.S.G, M.A.G., A.H.L., H.K., M.K., L.B.B., D.S., M.C.A. contributed patient
668 samples and/or data. M.D. wrote the manuscript. All authors read and approved the manuscript.

669

670 **DISCLOSURES**

671 All authors, with the exception of M. Altman and P. Becker, report grants from NIH/NIAID during the
672 conduct of study. M. Dapas, C. Visness, A. Calatroni and P. Becker have nothing to disclose outside the
673 submitted work. C. Ober reports personal fees from American Association of Asthma, Allergy and
674 Immunology, outside the submitted work. M. Altman reports personal fees from Sanofi-Regeneron
675 outside the submitted work. W. Busse reports personal fees from Boston Scientific, Novartis, Glaxo
676 SmithKline, Genentech, Sanofi/Genzyme, AstraZeneca, Teva, Regeneron and Elsevier outside the
677 submitted work. M. Gill reports an honorarium for and support for travel to the 2017 AAAAI meeting
678 during the conduct of study and monetary compensation from the American Academy of Pediatrics for
679 her work teaching the biannual Pediatrics board review course, PREP The Course. K. Hershey reports
680 grants from Adare, during the conduct of the study. D. Jackson reports personal fees from Novartis,
681 Boehringer Ingelheim, Pfizer, Regeneron, AstraZeneca, Sanofi and Vifor Pharma, grants and personal
682 fees from GlaxoSmithKline and grants from NIH/NHLBI, outside the submitted work. M. Kattan reports
683 personal fees from Regeneron, outside the submitted work. R. Gruchalla reports government employment
684 from Center for Biologics Evaluation and Research as well as personal fees from Consulting
685 Massachusetts Medical Society, outside the submitted work. A. Liu reports personal fees from Phadia
686 ThermoFisher as consulting honoraria, grants and non-financial support from ResMed/Propeller Health,
687 non-financial support from Revenio, grants and personal fees from Avillion and personal fees from
688 Labcorp, outside the submitted work. L. Bacharier reports personal fees from GlaxoSmithKline,
689 Genentech/Novartis, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape,
690 Sanofi/Regeneron, Vectura and geCircassia and personal fees and non-financial support from
691 Merck outside the submitted work. J. Gern reports personal fees from AstraZeneca and Gossamer Bio and
692 personal fees and stock options from Meissa Vaccines Inc, outside the submitted work. In addition, Dr.

693 Gern has a patent Methods of Propagating Rhinovirus C in Previously Unsusceptible Cell Lines issued,
694 and a patent Adapted Rhinovirus C issued. G. O'Connor reports personal fees from AstraZeneca and
695 grants from Janssen Pharmaceuticals, outside the submitted work. R. Wood reports grants from DBV,
696 Aimmune, Astellas, HAL-Allergy and Regeneron and royalties from Up to Date, outside the submitted
697 work. Dr. Becker's co-authorship of this publication does not necessarily constitute endorsement by the
698 National Institute of Allergy and Infectious Diseases, the National Institutes of Health or any other agency
699 of the United States government.
700

701 **REFERENCES**

- 702 1. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung
703 function and mortality risk in men and women: findings from the Renfrew and Paisley
704 prospective population study. *BMJ*. 1996;313(7059):711-5; discussion 5-6.
- 705 2. Schunemann HJ, Dorn J, Grant BJ, Winkelstein W, Jr., Trevisan M. Pulmonary function is
706 a long-term predictor of mortality in the general population: 29-year follow-up of the
707 Buffalo Health Study. *Chest*. 2000;118(3):656-64.
- 708 3. Mannino DM, Holguin F, Pavlin BI, Ferdinands JM. Risk factors for prevalence of and
709 mortality related to restriction on spirometry: findings from the First National Health and
710 Nutrition Examination Survey and follow-up. *Int J Tuberc Lung Dis*. 2005;9(6):613-21.
- 711 4. Chinn S, Gislason T, Aspelund T, Gudnason V. Optimum expression of adult lung function
712 based on all-cause mortality: results from the Reykjavik study. *Respir Med*.
713 2007;101(3):601-9.
- 714 5. Miller MR, Pedersen OF, Lange P, Vestbo J. Improved survival prediction from lung
715 function data in a large population sample. *Respir Med*. 2009;103(3):442-8.
- 716 6. Agusti A, Noell G, Brugada J, Faner R. Lung function in early adulthood and health in later
717 life: a transgenerational cohort analysis. *Lancet Respir Med*. 2017;5(12):935-45.
- 718 7. Stern DA, Morgan WJ, Wright AL, Guerra S, Martinez FD. Poor airway function in early
719 infancy and lung function by age 22 years: a non-selective longitudinal cohort study.
720 *Lancet*. 2007;370(9589):758-64.
- 721 8. Stocks J, Hislop A, Sonnappa S. Early lung development: lifelong effect on respiratory
722 health and disease. *Lancet Respir Med*. 2013;1(9):728-42.
- 723 9. McGeachie MJ, Yates KP, Zhou X, Guo F, Sternberg AL, Van Natta ML, et al. Patterns of
724 Growth and Decline in Lung Function in Persistent Childhood Asthma. *N Engl J Med*.
725 2016;374(19):1842-52.
- 726 10. Agusti A, Faner R. Lung function trajectories in health and disease. *Lancet Respir Med*.
727 2019;7(4):358-64.
- 728 11. Bisgaard H, Jensen SM, Bonnelykke K. Interaction between asthma and lung function
729 growth in early life. *Am J Respir Crit Care Med*. 2012;185(11):1183-9.
- 730 12. Duijts L, Reiss IK, Brusselle G, de Jongste JC. Early origins of chronic obstructive lung
731 diseases across the life course. *Eur J Epidemiol*. 2014;29(12):871-85.
- 732 13. Klimentidis YC, Vazquez AI, de Los Campos G, Allison DB, Dransfield MT, Thannickal
733 VJ. Heritability of pulmonary function estimated from pedigree and whole-genome
734 markers. *Front Genet*. 2013;4:174.

- 735 14. Wilk JB, Chen TH, Gottlieb DJ, Walter RE, Nagle MW, Brandler BJ, et al. A genome-
736 wide association study of pulmonary function measures in the Framingham Heart Study.
737 PLoS Genet. 2009;5(3):e1000429.
- 738 15. Repapi E, Sayers I, Wain LV, Burton PR, Johnson T, Obeidat M, et al. Genome-wide
739 association study identifies five loci associated with lung function. Nat Genet.
740 2010;42(1):36-44.
- 741 16. Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marciante KD, et al. Meta-
742 analyses of genome-wide association studies identify multiple loci associated with
743 pulmonary function. Nat Genet. 2010;42(1):45-52.
- 744 17. Soler Artigas M, Loth DW, Wain LV, Gharib SA, Obeidat M, Tang W, et al. Genome-wide
745 association and large-scale follow up identifies 16 new loci influencing lung function. Nat
746 Genet. 2011;43(11):1082-90.
- 747 18. Yao TC, Du G, Han L, Sun Y, Hu D, Yang JJ, et al. Genome-wide association study of
748 lung function phenotypes in a founder population. J Allergy Clin Immunol.
749 2014;133(1):248-55 e1-10.
- 750 19. Loth DW, Soler Artigas M, Gharib SA, Wain LV, Franceschini N, Koch B, et al. Genome-
751 wide association analysis identifies six new loci associated with forced vital capacity. Nat
752 Genet. 2014;46(7):669-77.
- 753 20. Wain LV, Shrine N, Artigas MS, Erzurumluoglu AM, Noyvert B, Bossini-Castillo L, et al.
754 Genome-wide association analyses for lung function and chronic obstructive pulmonary
755 disease identify new loci and potential druggable targets. Nat Genet. 2017;49(3):416-25.
- 756 21. Burkart KM, Sofer T, London SJ, Manichaikul A, Hartwig FP, Yan Q, et al. A Genome-
757 Wide Association Study in Hispanics/Latinos Identifies Novel Signals for Lung Function.
758 The Hispanic Community Health Study/Study of Latinos. Am J Respir Crit Care Med.
759 2018;198(2):208-19.
- 760 22. Wyss AB, Sofer T, Lee MK, Terzikhan N, Nguyen JN, Lahousse L, et al. Multiethnic
761 meta-analysis identifies ancestry-specific and cross-ancestry loci for pulmonary function.
762 Nat Commun. 2018;9(1):2976.
- 763 23. Shrine N, Guyatt AL, Erzurumluoglu AM, Jackson VE, Hobbs BD, Melbourne CA, et al.
764 New genetic signals for lung function highlight pathways and chronic obstructive
765 pulmonary disease associations across multiple ancestries. Nat Genet. 2019;51(3):481-93.
- 766 24. Akenroye AT, Brunetti T, Romero K, Daya M, Kanchan K, Shankar G, et al. Genome-wide
767 association study of asthma, total IgE, and lung function in a cohort of Peruvian children. J
768 Allergy Clin Immunol. 2021. doi: 10.1016/j.jaci.2021.02.035.
- 769 25. Zhu Z, Li J, Si J, Ma B, Shi H, Lv J, et al. A large-scale genome-wide association analysis
770 of lung function in the Chinese population identifies novel loci and highlights shared
771 genetic aetiology with obesity. Eur Respir J. 2021;58(4).

- 772 26. Obeidat M, Hao K, Bosse Y, Nickle DC, Nie Y, Postma DS, et al. Molecular mechanisms
773 underlying variations in lung function: a systems genetics analysis. *Lancet Respir Med.*
774 2015;3(10):782-95.
- 775 27. Gharib SA, Loth DW, Soler Artigas M, Birkland TP, Wilk JB, Wain LV, et al. Integrative
776 pathway genomics of lung function and airflow obstruction. *Hum Mol Genet.*
777 2015;24(23):6836-48.
- 778 28. Portas L, Pereira M, Shaheen SO, Wyss AB, London SJ, Burney PGJ, et al. Lung
779 Development Genes and Adult Lung Function. *Am J Respir Crit Care Med.*
780 2020;202(6):853-65.
- 781 29. Kheirallah AK, Miller S, Hall IP, Sayers I. Translating Lung Function Genome-Wide
782 Association Study (GWAS) Findings: New Insights for Lung Biology. *Adv Genet.*
783 2016;93:57-145.
- 784 30. Aschard H, Tobin MD, Hancock DB, Skurnik D, Sood A, James A, et al. Evidence for
785 large-scale gene-by-smoking interaction effects on pulmonary function. *Int J Epidemiol.*
786 2017;46(3):894-904.
- 787 31. Park B, An J, Kim W, Kang HY, Koh SB, Oh B, et al. Effect of 6p21 region on lung
788 function is modified by smoking: a genome-wide interaction study. *Sci Rep.*
789 2020;10(1):13075.
- 790 32. Kim W, Moll M, Qiao D, Hobbs BD, Shrine N, Sakornsakolpat P, et al. Smoking
791 Interaction with a Polygenic Risk Score for Reduced Lung Function. *medRxiv.* 2021. doi:
792 10.1101/2021.03.26.21254415:2021.03.26.21254415.
- 793 33. Melbourne CA, Erzurumluoglu AM, Shrine N, Chen J, Tobin MD, Hansell A, et al.
794 Genome-wide gene-air pollution interaction analysis of lung function in 300,000
795 individuals. *medRxiv.* 2021. doi: 10.1101/2021.06.03.21256376:2021.06.03.21256376.
- 796 34. Miller MD, Marty MA. Impact of environmental chemicals on lung development. *Environ*
797 *Health Perspect.* 2010;118(8):1155-64.
- 798 35. Decrue F, Gorlanova O, Usemann J, Frey U. Lung functional development and asthma
799 trajectories. *Semin Immunopathol.* 2020;42(1):17-27.
- 800 36. He Z, Wu H, Zhang S, Lin Y, Li R, Xie L, et al. The association between secondhand
801 smoke and childhood asthma: A systematic review and meta-analysis. *Pediatr Pulmonol.*
802 2020;55(10):2518-31.
- 803 37. Thacher JD, Schultz ES, Hallberg J, Hellberg U, Kull I, Thunqvist P, et al. Tobacco smoke
804 exposure in early life and adolescence in relation to lung function. *Eur Respir J.*
805 2018;51(6).

- 806 38. Dratva J, Zemp E, Dharmage SC, Accordini S, Burdet L, Gislason T, et al. Early Life
807 Origins of Lung Ageing: Early Life Exposures and Lung Function Decline in Adulthood in
808 Two European Cohorts Aged 28-73 Years. *PLoS One*. 2016;11(1):e0145127.
- 809 39. Savran O, Ulrik CS. Early life insults as determinants of chronic obstructive pulmonary
810 disease in adult life. *Int J Chron Obstruct Pulmon Dis*. 2018;13:683-93.
- 811 40. Zeilinger S, Kuhnel B, Klopp N, Baurecht H, Kleinschmidt A, Gieger C, et al. Tobacco
812 smoking leads to extensive genome-wide changes in DNA methylation. *PLoS One*.
813 2013;8(5):e63812.
- 814 41. Rider CF, Carlsten C. Air pollution and DNA methylation: effects of exposure in humans.
815 *Clin Epigenetics*. 2019;11(1):131.
- 816 42. Jamieson E, Korologou-Linden R, Wootton RE, Guyatt AL, Battram T, Burrows K, et al.
817 Smoking, DNA Methylation, and Lung Function: a Mendelian Randomization Analysis to
818 Investigate Causal Pathways. *Am J Hum Genet*. 2020;106(3):315-26.
- 819 43. Kwak SY, Park CY, Shin MJ. Smoking May Affect Pulmonary Function through DNA
820 Methylation: an Epigenome-Wide Association Study in Korean Men. *Clin Nutr Res*.
821 2020;9(2):134-44.
- 822 44. Sunny SK, Zhang H, Relton CL, Ring S, Kadalayil L, Mzayek F, et al. Sex-specific
823 longitudinal association of DNA methylation with lung function. *ERJ Open Res*. 2021;7(3).
- 824 45. Mukherjee N, Lockett GA, Merid SK, Melen E, Pershagen G, Holloway JW, et al. DNA
825 methylation and genetic polymorphisms of the Leptin gene interact to influence lung
826 function outcomes and asthma at 18 years of age. *Int J Mol Epidemiol Genet*. 2016;7(1):1-
827 17.
- 828 46. Zhang H, Tong X, Holloway JW, Rezwani FI, Lockett GA, Patil V, et al. The interplay of
829 DNA methylation over time with Th2 pathway genetic variants on asthma risk and
830 temporal asthma transition. *Clin Epigenetics*. 2014;6(1):8.
- 831 47. Munoz-Pizza DM, Villada-Canela M, Reyna MA, Texcalac-Sangrador JL, Osornio-Vargas
832 AR. Air pollution and children's respiratory health: a scoping review of socioeconomic
833 status as an effect modifier. *Int J Public Health*. 2020;65(5):649-60.
- 834 48. Hajizadeh M, Nandi A. The socioeconomic gradient of secondhand smoke exposure in
835 children: evidence from 26 low-income and middle-income countries. *Tob Control*.
836 2016;25(e2):e146-e55.
- 837 49. Martinez CH, Mannino DM, Curtis JL, Han MK, Diaz AA. Socioeconomic Characteristics
838 Are Major Contributors to Ethnic Differences in Health Status in Obstructive Lung
839 Disease: An Analysis of the National Health and Nutrition Examination Survey 2007-2010.
840 *Chest*. 2015;148(1):151-8.

- 841 50. Thakur N, Oh SS, Nguyen EA, Martin M, Roth LA, Galanter J, et al. Socioeconomic status
842 and childhood asthma in urban minority youths. The GALA II and SAGE II studies. *Am J*
843 *Respir Crit Care Med*. 2013;188(10):1202-9.
- 844 51. Oraka E, Iqbal S, Flanders WD, Brinker K, Garbe P. Racial and ethnic disparities in current
845 asthma and emergency department visits: findings from the National Health Interview
846 Survey, 2001-2010. *J Asthma*. 2013;50(5):488-96.
- 847 52. Keet CA, Matsui EC, McCormack MC, Peng RD. Urban residence, neighborhood poverty,
848 race/ethnicity, and asthma morbidity among children on Medicaid. *J Allergy Clin*
849 *Immunol*. 2017;140(3):822-7.
- 850 53. Manrai AK, Funke BH, Rehm HL, Olesen MS, Maron BA, Szolovits P, et al. Genetic
851 Misdiagnoses and the Potential for Health Disparities. *N Engl J Med*. 2016;375(7):655-65.
- 852 54. Landry LG, Ali N, Williams DR, Rehm HL, Bonham VL. Lack Of Diversity In Genomic
853 Databases Is A Barrier To Translating Precision Medicine Research Into Practice. *Health*
854 *Aff (Millwood)*. 2018;37(5):780-5.
- 855 55. Pongracic JA, Krouse RZ, Babineau DC, Zoratti EM, Cohen RT, Wood RA, et al.
856 Distinguishing characteristics of difficult-to-control asthma in inner-city children and
857 adolescents. *J Allergy Clin Immunol*. 2016;138(4):1030-41.
- 858 56. Zoratti EM, Krouse RZ, Babineau DC, Pongracic JA, O'Connor GT, Wood RA, et al.
859 Asthma phenotypes in inner-city children. *J Allergy Clin Immunol*. 2016;138(4):1016-29.
- 860 57. Gern JE, Visness CM, Gergen PJ, Wood RA, Bloomberg GR, O'Connor GT, et al. The
861 Urban Environment and Childhood Asthma (URECA) birth cohort study: design, methods,
862 and study population. *BMC Pulm Med*. 2009;9:17.
- 863 58. Zhou X, Stephens M. Genome-wide efficient mixed-model analysis for association studies.
864 *Nat Genet*. 2012;44(7):821-4.
- 865 59. Consortium EP, Moore JE, Purcaro MJ, Pratt HE, Epstein CB, Shores N, et al. Expanded
866 encyclopaedias of DNA elements in the human and mouse genomes. *Nature*.
867 2020;583(7818):699-710.
- 868 60. Ma M, Ru Y, Chuang LS, Hsu NY, Shi LS, Hakenberg J, et al. Disease-associated variants
869 in different categories of disease located in distinct regulatory elements. *BMC Genomics*.
870 2015;16 Suppl 8:S3.
- 871 61. Boyle EA, Li YI, Pritchard JK. An Expanded View of Complex Traits: From Polygenic to
872 Omnigenic. *Cell*. 2017;169(7):1177-86.
- 873 62. Watanabe K, Stringer S, Frei O, Umicevic Mirkov M, de Leeuw C, Polderman TJC, et al.
874 A global overview of pleiotropy and genetic architecture in complex traits. *Nat Genet*.
875 2019;51(9):1339-48.

- 876 63. Schulz H, Ruppert AK, Herms S, Wolf C, Mirza-Schreiber N, Stegle O, et al. Genome-
877 wide mapping of genetic determinants influencing DNA methylation and gene expression
878 in human hippocampus. *Nat Commun.* 2017;8(1):1511.
- 879 64. Huan T, Joehanes R, Song C, Peng F, Guo Y, Mendelson M, et al. Genome-wide
880 identification of DNA methylation QTLs in whole blood highlights pathways for
881 cardiovascular disease. *Nat Commun.* 2019;10(1):4267.
- 882 65. Hannon E, Gorrie-Stone TJ, Smart MC, Burrage J, Hughes A, Bao Y, et al. Leveraging
883 DNA-Methylation Quantitative-Trait Loci to Characterize the Relationship between
884 Methyloomic Variation, Gene Expression, and Complex Traits. *Am J Hum Genet.*
885 2018;103(5):654-65.
- 886 66. McKennan C, Naughton K, Stanhope C, Kattan M, O'Connor GT, Sandel MT, et al.
887 Longitudinal data reveal strong genetic and weak non-genetic components of ethnicity-
888 dependent blood DNA methylation levels. *Epigenetics.* 2021;16(6):662-76.
- 889 67. Joubert BR, Felix JF, Yousefi P, Bakulski KM, Just AC, Breton C, et al. DNA Methylation
890 in Newborns and Maternal Smoking in Pregnancy: Genome-wide Consortium Meta-
891 analysis. *Am J Hum Genet.* 2016;98(4):680-96.
- 892 68. Sikdar S, Joehanes R, Joubert BR, Xu CJ, Vives-Usano M, Rezwan FI, et al. Comparison
893 of smoking-related DNA methylation between newborns from prenatal exposure and adults
894 from personal smoking. *Epigenomics.* 2019;11(13):1487-500.
- 895 69. Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ. Trait-associated SNPs are
896 more likely to be eQTLs: annotation to enhance discovery from GWAS. *PLoS Genet.*
897 2010;6(4):e1000888.
- 898 70. Yao DW, O'Connor LJ, Price AL, Gusev A. Quantifying genetic effects on disease
899 mediated by assayed gene expression levels. *Nat Genet.* 2020;52(6):626-33.
- 900 71. Hormozdiari F, van de Bunt M, Segre AV, Li X, Joo JWJ, Bilow M, et al. Colocalization
901 of GWAS and eQTL Signals Detects Target Genes. *Am J Hum Genet.* 2016;99(6):1245-60.
- 902 72. Helling BA, Sobreira DR, Hansen GT, Sakabe NJ, Luo K, Billstrand C, et al. Altered
903 transcriptional and chromatin responses to rhinovirus in bronchial epithelial cells from
904 adults with asthma. *Commun Biol.* 2020;3(1):678.
- 905 73. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, et al.
906 ASPP proteins specifically stimulate the apoptotic function of p53. *Mol Cell.*
907 2001;8(4):781-94.
- 908 74. Aylon Y, Ofir-Rosenfeld Y, Yabuta N, Lapi E, Nojima H, Lu X, et al. The Lats2 tumor
909 suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic
910 function of ASPP1. *Genes Dev.* 2010;24(21):2420-9.

- 911 75. Wang Y, Godin-Heymann N, Dan Wang X, Bergamaschi D, Llanos S, Lu X. ASPP1 and
912 ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer
913 cells. *Cell Death Differ.* 2013;20(4):525-34.
- 914 76. Xue H, Li MX. MicroRNA-150 protects against cigarette smoke-induced lung
915 inflammation and airway epithelial cell apoptosis through repressing p53: MicroRNA-150
916 in CS-induced lung inflammation. *Hum Exp Toxicol.* 2018;37(9):920-8.
- 917 77. Xu F, Xu A, Guo Y, Bai Q, Wu X, Ji SP, et al. PM2.5 exposure induces alveolar epithelial
918 cell apoptosis and causes emphysema through p53/Siva-1. *Eur Rev Med Pharmacol Sci.*
919 2020;24(7):3943-50.
- 920 78. Song Q, Zhou ZJ, Cai S, Chen Y, Chen P. Oxidative stress links the tumour suppressor p53
921 with cell apoptosis induced by cigarette smoke. *Int J Environ Health Res.* 2021. doi:
922 10.1080/09603123.2021.1910211:1-11.
- 923 79. Zhao K, Yu M, Zhu Y, Liu D, Wu Q, Hu Y. EGR-1/ASPP1 inter-regulatory loop promotes
924 apoptosis by inhibiting cyto-protective autophagy. *Cell Death Dis.* 2017;8(6):e2869.
- 925 80. Reynolds PR, Cosio MG, Hoidal JR. Cigarette smoke-induced Egr-1 upregulates
926 proinflammatory cytokines in pulmonary epithelial cells. *Am J Respir Cell Mol Biol.*
927 2006;35(3):314-9.
- 928 81. Chen ZH, Kim HP, Sciruba FC, Lee SJ, Feghali-Bostwick C, Stolz DB, et al. Egr-1
929 regulates autophagy in cigarette smoke-induced chronic obstructive pulmonary disease.
930 *PLoS One.* 2008;3(10):e3316.
- 931 82. Shen N, Gong T, Wang JD, Meng FL, Qiao L, Yang RL, et al. Cigarette smoke-induced
932 pulmonary inflammatory responses are mediated by EGR-1/GGPPS/MAPK signaling. *Am*
933 *J Pathol.* 2011;178(1):110-8.
- 934 83. Wang SB, Zhang C, Xu XC, Xu F, Zhou JS, Wu YP, et al. Early growth response factor 1
935 is essential for cigarette smoke-induced MUC5AC expression in human bronchial
936 epithelial cells. *Biochem Biophys Res Commun.* 2017;490(2):147-54.
- 937 84. Xu F, Cao J, Luo M, Che L, Li W, Ying S, et al. Early growth response gene 1 is essential
938 for urban particulate matter-induced inflammation and mucus hyperproduction in airway
939 epithelium. *Toxicol Lett.* 2018;294:145-55.
- 940 85. Golebski K, Gorenjak M, Kabesch M, Maitland-Van Der Zee A-H, Melén E, Potočnik U,
941 et al. EGR-1 as a potential biomarker in asthma and proinflammatory responses in airway
942 epithelium. *European Respiratory Journal.* 2021;58(suppl 65):PA2041.
- 943 86. Wang A, Chiou J, Poirion OB, Buchanan J, Valdez MJ, Verheyden JM, et al. Single-cell
944 multiomic profiling of human lungs reveals cell-type-specific and age-dynamic control of
945 SARS-CoV2 host genes. *Elife.* 2020;9.

- 946 87. Karlsson M, Zhang C, Mear L, Zhong W, Digre A, Katona B, et al. A single-cell type
947 transcriptomics map of human tissues. *Sci Adv.* 2021;7(31).
- 948 88. Cheng Y, Luo W, Li Z, Cao M, Zhu Z, Han C, et al. CircRNA-012091/PPP1R13B-
949 mediated Lung Fibrotic Response in Silicosis via Endoplasmic Reticulum Stress and
950 Autophagy. *Am J Respir Cell Mol Biol.* 2019;61(3):380-91.
- 951 89. Vigneron AM, Ludwig RL, Vousden KH. Cytoplasmic ASPP1 inhibits apoptosis through
952 the control of YAP. *Genes Dev.* 2010;24(21):2430-9.
- 953 90. Manfredi JJ. An identity crisis for a cancer gene: subcellular location determines ASPP1
954 function. *Cancer Cell.* 2010;18(5):409-10.
- 955 91. Fogal V, Kartasheva NN, Trigiante G, Llanos S, Yap D, Vousden KH, et al. ASPP1 and
956 ASPP2 are new transcriptional targets of E2F. *Cell Death Differ.* 2005;12(4):369-76.
- 957 92. Zhou SJ, Li M, Zeng DX, Zhu ZM, Hu XW, Li YH, et al. Expression variations of
958 connective tissue growth factor in pulmonary arteries from smokers with and without
959 chronic obstructive pulmonary disease. *Sci Rep.* 2015;5:8564.
- 960 93. Eguchi A, Nishizawa-Jotaki S, Tanabe H, Rahmutulla B, Watanabe M, Miyaso H, et al. An
961 Altered DNA Methylation Status in the Human Umbilical Cord Is Correlated with
962 Maternal Exposure to Polychlorinated Biphenyls. *Int J Environ Res Public Health.*
963 2019;16(15).
- 964 94. Pierce BL, Tong L, Argos M, Demanelis K, Jasmine F, Rakibuz-Zaman M, et al. Co-
965 occurring expression and methylation QTLs allow detection of common causal variants and
966 shared biological mechanisms. *Nat Commun.* 2018;9(1):804.
- 967 95. Philibert RA, Sears RA, Powers LS, Nash E, Bair T, Gerke AK, et al. Coordinated DNA
968 methylation and gene expression changes in smoker alveolar macrophages: specific effects
969 on VEGF receptor 1 expression. *J Leukoc Biol.* 2012;92(3):621-31.
- 970 96. Guijo M, Ceballos-Chavez M, Gomez-Marin E, Basurto-Cayuela L, Reyes JC. Expression
971 of TDRD9 in a subset of lung carcinomas by CpG island hypomethylation protects from
972 DNA damage. *Oncotarget.* 2018;9(11):9618-31.
- 973 97. Consortium GT. The Genotype-Tissue Expression (GTEx) project. *Nat Genet.*
974 2013;45(6):580-5.
- 975 98. Loh K, Modhukur V, Rajashekar B, Martens K, Magi R, Kolde R, et al. DNA methylome
976 profiling of human tissues identifies global and tissue-specific methylation patterns.
977 *Genome Biol.* 2014;15(4):r54.
- 978 99. Wan J, Oliver VF, Wang G, Zhu H, Zack DJ, Merbs SL, et al. Characterization of tissue-
979 specific differential DNA methylation suggests distinct modes of positive and negative
980 gene expression regulation. *BMC Genomics.* 2015;16:49.

- 981 100. den Dekker HT, Burrows K, Felix JF, Salas LA, Nedeljkovic I, Yao J, et al. Newborn
982 DNA-methylation, childhood lung function, and the risks of asthma and COPD across the
983 life course. *Eur Respir J.* 2019;53(4).
- 984 101. Imboden M, Wielscher M, Rezwani FI, Amaral AFS, Schaffner E, Jeong A, et al.
985 Epigenome-wide association study of lung function level and its change. *Eur Respir J.*
986 2019;54(1).
- 987 102. Mukherjee N, Arathimos R, Chen S, Kheirkhah Rahimabad P, Han L, Zhang H, et al. DNA
988 methylation at birth is associated with lung function development until age 26 years. *Eur*
989 *Respir J.* 2021;57(4).
- 990 103. Wang T, Wang W, Li W, Duan H, Xu C, Tian X, et al. Genome-wide DNA methylation
991 analysis of pulmonary function in middle and old-aged Chinese monozygotic twins. *Respir*
992 *Res.* 2021;22(1):300.
- 993 104. Herrera-Luis E, Li A, Mak ACY, Perez-Garcia J, Elhawary JR, Oh SS, et al. Epigenome-
994 wide association study of lung function in Latino children and youth with asthma. *Clin*
995 *Epigenetics.* 2022;14(1):9.
- 996 105. Cosin-Tomas M, Bustamante M, Sunyer J. Epigenetic association studies at birth and the
997 origin of lung function development. *Eur Respir J.* 2021;57(4).
- 998 106. Yang IV, Lozupone CA, Schwartz DA. The environment, epigenome, and asthma. *J*
999 *Allergy Clin Immunol.* 2017;140(1):14-23.
- 1000 107. Lin PI, Shu H, Mersha TB. Comparing DNA methylation profiles across different tissues
1001 associated with the diagnosis of pediatric asthma. *Sci Rep.* 2020;10(1):151.
- 1002 108. Richmond RC, Davey Smith G. Mendelian Randomization: Concepts and Scope. *Cold*
1003 *Spring Harb Perspect Med.* 2022;12(1).
- 1004 109. Robins JM, Greenland S. Identifiability and exchangeability for direct and indirect effects.
1005 *Epidemiology.* 1992;3(2):143-55.
- 1006 110. Li YF, Gilliland FD, Berhane K, McConnell R, Gauderman WJ, Rappaport EB, et al.
1007 Effects of in utero and environmental tobacco smoke exposure on lung function in boys
1008 and girls with and without asthma. *Am J Respir Crit Care Med.* 2000;162(6):2097-104.
- 1009 111. Gilliland FD, Berhane K, Li YF, Rappaport EB, Peters JM. Effects of early onset asthma
1010 and in utero exposure to maternal smoking on childhood lung function. *Am J Respir Crit*
1011 *Care Med.* 2003;167(6):917-24.
- 1012 112. Schultz ES, Litonjua AA, Melen E. Effects of Long-Term Exposure to Traffic-Related Air
1013 Pollution on Lung Function in Children. *Curr Allergy Asthma Rep.* 2017;17(6):41.
- 1014 113. Kreiner-Moller E, Bisgaard H, Bonnelykke K. Prenatal and postnatal genetic influence on
1015 lung function development. *J Allergy Clin Immunol.* 2014;134(5):1036-42 e15.

- 1016 114. Lee EY, Mak ACY, Hu D, Sajuthi S, White MJ, Keys KL, et al. Whole-Genome
1017 Sequencing Identifies Novel Functional Loci Associated with Lung Function in Puerto
1018 Rican Youth. *Am J Respir Crit Care Med.* 2020;202(7):962-72.
- 1019 115. Goddard PC, Keys KL, Mak ACY, Lee EY, Liu AK, Samedy-Bates LA, et al. Integrative
1020 genomic analysis in African American children with asthma finds three novel loci
1021 associated with lung function. *Genet Epidemiol.* 2021;45(2):190-208.
- 1022 116. Akenroye AT, Brunetti T, Romero K, Daya M, Kanchan K, Shankar G, et al. Genome-wide
1023 association study of asthma, total IgE, and lung function in a cohort of Peruvian children. *J*
1024 *Allergy Clin Immunol.* 2021;148(6):1493-504.
- 1025 117. Imboden M, Bouzigon E, Curjuric I, Ramasamy A, Kumar A, Hancock DB, et al. Genome-
1026 wide association study of lung function decline in adults with and without asthma. *J*
1027 *Allergy Clin Immunol.* 2012;129(5):1218-28.
- 1028 118. Aschard H, Vilhjalmsdottir BJ, Joshi AD, Price AL, Kraft P. Adjusting for heritable
1029 covariates can bias effect estimates in genome-wide association studies. *Am J Hum Genet.*
1030 2015;96(2):329-39.
- 1031 119. Jones MJ, Goodman SJ, Kobor MS. DNA methylation and healthy human aging. *Aging*
1032 *Cell.* 2015;14(6):924-32.
- 1033 120. Ambatipudi S, Cuenin C, Hernandez-Vargas H, Ghantous A, Le Calvez-Kelm F, Kaaks R,
1034 et al. Tobacco smoking-associated genome-wide DNA methylation changes in the EPIC
1035 study. *Epigenomics.* 2016;8(5):599-618.
- 1036 121. Tommasi S, Zheng A, Besaratinia A. Exposure of mice to secondhand smoke elicits both
1037 transient and long-lasting transcriptional changes in cancer-related functional networks. *Int*
1038 *J Cancer.* 2015;136(10):2253-63.
- 1039 122. Sridhar S, Schembri F, Zeskind J, Shah V, Gustafson AM, Steiling K, et al. Smoking-
1040 induced gene expression changes in the bronchial airway are reflected in nasal and buccal
1041 epithelium. *BMC Genomics.* 2008;9:259.
- 1042 123. Zhang X, Sebastiani P, Liu G, Schembri F, Zhang X, Dumas YM, et al. Similarities and
1043 differences between smoking-related gene expression in nasal and bronchial epithelium.
1044 *Physiol Genomics.* 2010;41(1):1-8.
- 1045 124. Brugha R, Lowe R, Henderson AJ, Holloway JW, Rakyan V, Wozniak E, et al. DNA
1046 methylation profiles between airway epithelium and proxy tissues in children. *Acta*
1047 *Paediatr.* 2017;106(12):2011-6.
- 1048 125. Imkamp K, Berg M, Vermeulen CJ, Heijink IH, Guryev V, Kerstjens HAM, et al. Nasal
1049 epithelium as a proxy for bronchial epithelium for smoking-induced gene expression and
1050 expression Quantitative Trait Loci. *J Allergy Clin Immunol.* 2018;142(1):314-7 e15.

- 1051 126. Kicic A, de Jong E, Ling KM, Nichol K, Anderson D, Wark PAB, et al. Assessing the
1052 unified airway hypothesis in children via transcriptional profiling of the airway epithelium.
1053 *J Allergy Clin Immunol.* 2020;145(6):1562-73.
- 1054 127. Bergounoux A, Claustres M, De Sario A. Nasal epithelial cells: a tool to study DNA
1055 methylation in airway diseases. *Epigenomics.* 2015;7(1):119-26.
- 1056 128. Gergen PJ, Teach SJ, Togias A, Busse WW. Reducing Exacerbations in the Inner City:
1057 Lessons from the Inner-City Asthma Consortium (ICAC). *J Allergy Clin Immunol Pract.*
1058 2016;4(1):22-6.
- 1059 129. O'Connor GT, Lynch SV, Bloomberg GR, Kattan M, Wood RA, Gergen PJ, et al. Early-
1060 life home environment and risk of asthma among inner-city children. *J Allergy Clin*
1061 *Immunol.* 2018;141(4):1468-75.
- 1062 130. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic
1063 reference values for spirometry for the 3-95-yr age range: the global lung function 2012
1064 equations. *Eur Respir J.* 2012;40(6):1324-43.
- 1065 131. Bernert JT, Harmon TL, Sosnoff CS, McGuffey JE. Use of cotinine immunoassay test
1066 strips for preclassifying urine samples from smokers and nonsmokers prior to analysis by
1067 LC-MS-MS. *J Anal Toxicol.* 2005;29(8):814-8.
- 1068 132. Regier AA, Farjoun Y, Larson DE, Krasheninina O, Kang HM, Howrigan DP, et al.
1069 Functional equivalence of genome sequencing analysis pipelines enables harmonized
1070 variant calling across human genetics projects. *Nat Commun.* 2018;9(1):4038.
- 1071 133. Kowalski MH, Qian H, Hou Z, Rosen JD, Tapia AL, Shan Y, et al. Use of >100,000
1072 NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium whole genome
1073 sequences improves imputation quality and detection of rare variant associations in
1074 admixed African and Hispanic/Latino populations. *PLoS Genet.* 2019;15(12):e1008500.
- 1075 134. Zhang F, Flickinger M, Taliun SAG, In PPGC, Abecasis GR, Scott LJ, et al. Ancestry-
1076 agnostic estimation of DNA sample contamination from sequence reads. *Genome Res.*
1077 2020;30(2):185-94.
- 1078 135. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
1079 PLINK: rising to the challenge of larger and richer datasets. *Gigascience.* 2015;4:7.
- 1080 136. McKennan C, Naughton K, Stanhope C, Kattan M, O'Connor GT, Sandel MT, et al.
1081 Longitudinal data reveal strong genetic and weak non-genetic components of ethnicity-
1082 dependent blood DNA methylation levels. *Epigenetics.* 2020. doi:
1083 10.1080/15592294.2020.1817290:1-15.
- 1084 137. Jun G, Flickinger M, Hetrick KN, Romm JM, Doheny KF, Abecasis GR, et al. Detecting
1085 and estimating contamination of human DNA samples in sequencing and array-based
1086 genotype data. *Am J Hum Genet.* 2012;91(5):839-48.

- 1087 138. Hao W, Storey JD. Extending Tests of Hardy-Weinberg Equilibrium to Structured
1088 Populations. *Genetics*. 2019;213(3):759-70.
- 1089 139. Danecek P, Auton A, Abecasis G, Albers CA, Banks E, DePristo MA, et al. The variant
1090 call format and VCFtools. *Bioinformatics*. 2011;27(15):2156-8.
- 1091 140. Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al. Twelve years of
1092 SAMtools and BCFtools. *Gigascience*. 2021;10(2).
- 1093 141. Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A
1094 global reference for human genetic variation. *Nature*. 2015;526(7571):68-74.
- 1095 142. Bergstrom A, McCarthy SA, Hui R, Almarri MA, Ayub Q, Danecek P, et al. Insights into
1096 human genetic variation and population history from 929 diverse genomes. *Science*.
1097 2020;367(6484).
- 1098 143. Alexander DH, Novembre J, Lange K. Fast model-based estimation of ancestry in
1099 unrelated individuals. *Genome Res*. 2009;19(9):1655-64.
- 1100 144. Conomos MP, Miller MB, Thornton TA. Robust inference of population structure for
1101 ancestry prediction and correction of stratification in the presence of relatedness. *Genet*
1102 *Epidemiol*. 2015;39(4):276-93.
- 1103 145. Conomos MP, Reiner AP, Weir BS, Thornton TA. Model-free Estimation of Recent
1104 Genetic Relatedness. *Am J Hum Genet*. 2016;98(1):127-48.
- 1105 146. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust relationship
1106 inference in genome-wide association studies. *Bioinformatics*. 2010;26(22):2867-73.
- 1107 147. Shringarpure SS, Bustamante CD, Lange K, Alexander DH. Efficient analysis of large
1108 datasets and sex bias with ADMIXTURE. *BMC Bioinformatics*. 2016;17:218.
- 1109 148. Sofer T, Zheng X, Gogarten SM, Laurie CA, Grinde K, Shaffer JR, et al. A fully adjusted
1110 two-stage procedure for rank-normalization in genetic association studies. *Genet*
1111 *Epidemiol*. 2019;43(3):263-75.
- 1112 149. McCaw ZR, Lane JM, Saxena R, Redline S, Lin X. Operating characteristics of the rank-
1113 based inverse normal transformation for quantitative trait analysis in genome-wide
1114 association studies. *Biometrics*. 2020;76(4):1262-72.
- 1115 150. Wang G, Sarkar A, Carbonetto P, Stephens M. A simple new approach to variable selection
1116 in regression, with application to genetic fine mapping. *Journal of the Royal Statistical*
1117 *Society: Series B (Statistical Methodology)*. 2020;82(5):1273-300.
- 1118 151. Shabalín AA. Matrix eQTL: ultra fast eQTL analysis via large matrix operations.
1119 *Bioinformatics*. 2012;28(10):1353-8.

- 1120 152. McKennan C, Nicolae D. Accounting for unobserved covariates with varying degrees of
1121 estimability in high-dimensional biological data. *Biometrika*. 2019;106(4):823-40.
- 1122 153. Zhang D. A Coefficient of Determination for Generalized Linear Models. *The American*
1123 *Statistician*. 2017;71(4):310-6.
- 1124 154. Fox J, Kleiber C, Zeileis A. ivreg: Two-Stage Least-Squares Regression with Diagnostics.
1125 <https://john-d-fox.github.io/ivreg/2021>.
- 1126 155. Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for
1127 Mendelian randomization. *Stat Methods Med Res*. 2017;26(5):2333-55.
- 1128 156. Burgess S, Thompson SG. Use of allele scores as instrumental variables for Mendelian
1129 randomization. *International Journal of Epidemiology*. 2013;42(4):1134-44.
- 1130 157. Alfons A, Ateş NY, Groenen PJF. A Robust Bootstrap Test for Mediation Analysis.
1131 *Organizational Research Methods*.0(0):1094428121999096.
- 1132 158. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast
1133 universal RNA-seq aligner. *Bioinformatics*. 2013;29(1):15-21.
- 1134 159. Law CW, Chen Y, Shi W, Smyth GK. voom: Precision weights unlock linear model
1135 analysis tools for RNA-seq read counts. *Genome Biol*. 2014;15(2):R29.
- 1136 160. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential
1137 expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res*.
1138 2015;43(7):e47.
- 1139 161. Jager R, Migliorini G, Henrion M, Kandaswamy R, Speedy HE, Heindl A, et al. Capture
1140 Hi-C identifies the chromatin interactome of colorectal cancer risk loci. *Nat Commun*.
1141 2015;6:6178.
- 1142 162. Mifsud B, Tavares-Cadete F, Young AN, Sugar R, Schoenfelder S, Ferreira L, et al.
1143 Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C.
1144 *Nat Genet*. 2015;47(6):598-606.
- 1145 163. Montefiori LE, Sobreira DR, Sakabe NJ, Aneas I, Joslin AC, Hansen GT, et al. A promoter
1146 interaction map for cardiovascular disease genetics. *Elife*. 2018;7.
- 1147 164. Cairns J, Freire-Pritchett P, Wingett SW, Varnai C, Dimond A, Plagnol V, et al.
1148 CHiCAGO: robust detection of DNA looping interactions in Capture Hi-C data. *Genome*
1149 *Biol*. 2016;17(1):127.
1150

1151 SUPPORTING INFORMATION

1152

1153 **S1 Fig. Whole-genome sequencing depth and coverage. A)** Histogram of 1,035 whole-
1154 genome sequencing (WGS) samples from APIC and URECA by mean depth of coverage. **B)**
1155 Histogram of WGS samples based on proportion of genome covered at 20x, 25x, and 30x
1156 depth. APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and
1157 Childhood Asthma study.

1158

1159

1160 **S1 Table. Post-QC sequencing call concordance between replicates.** Variant call
1161 concordance between three pairs of replicate samples, by variant type and cohort allele
1162 frequency. SNPs, single nucleotide polymorphisms; MAF, minor allele frequency; InDels,
1163 insertions and deletions.

1164

1165

1166 **S2 Table. FEV₁-associated variants in chr14q32.33.** All variants in chr14q32.33 associated
1167 with FEV₁ (% predicted) with $p < 1 \times 10^{-5}$ (n=82) in GWAS of 896 participants from APIC &
1168 URECA. N, number of genotyped individuals. MAF, minor allele frequency; 95% CI, 95%
1169 confidence interval; SE, standard error; P, P-value (Wald); FEV₁, forced expiratory volume in
1170 one second; APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment
1171 and Childhood Asthma study.

1172

1173

1174 **S2 Fig. Distribution of lung function measures by study. A)** Distribution of FEV₁ (%
1175 predicted) in APIC and URECA. **B)** Distribution of FEV₁/FVC in APIC and URECA. APIC,
1176 Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma
1177 study. FEV₁, forced expiratory volume in one second; FVC, forced vital capacity.

1178

1179

1180 **S3 Fig. P-value distributions of GWAS results.** Quantile-quantile plots of the GWAS results
1181 with corresponding genomic control factors (λ) are shown for A) FEV₁ (% predicted) and
1182 B) FEV₁/FVC. FEV₁, forced expiratory volume in one second; FVC, forced vital capacity.

1183

1184

1185 **S4 Fig. Fine-mapping results for FEV₁ (% predicted) at the *TDRD9* locus.** The X-axis shows
1186 the chromosome position on chromosome 14. The Y-axis is the posterior inclusion probability
1187 (PIP). Variants highlighted in red represent a credible set, in which there is a 95% probability
1188 that at least one of the variants is causal. FEV₁, forced expiratory volume in one second.

1189

1190

1191 **S5 Fig. Genome-wide association results without adjustment for asthma.** GWAS
1192 Manhattan plots for A) FEV₁ and B) FEV₁/FVC ratio, without adjustment for asthma status. The
1193 horizontal red line indicates genome-wide significance ($p \leq 2.5 \times 10^{-8}$). The dotted horizontal blue

1194 line indicates $p=1 \times 10^{-5}$. Variants colored in grey are the GWAS results with asthma adjustment.
1195 FEV₁, forced expiratory volume in one second; FEV₁/FVC, ratio of FEV₁ to forced vital capacity.

1196
1197

1198 **S6 Fig. Replication of FEV₁ GWAS SNPs.** Association statistics for previously identified FEV₁
1199 GWAS SNPs [23]. 64 out of 70 previously identified SNPs were genotyped in APIC & URECA.
1200 GWAS, genome-wide association study; SNP, single nucleotide polymorphism; APIC, Asthma
1201 Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma study.
1202 FEV₁, forced expiratory volume in one second.

1203
1204

1205 **S7 Fig. Replication of FEV₁/FVC GWAS SNPs.** Association statistics for previously identified
1206 FEV₁/FVC GWAS SNPs [23]. 112 out of 117 previously identified SNPs were genotyped in
1207 APIC & URECA. GWAS, genome-wide association study; SNP, single nucleotide
1208 polymorphism; APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment
1209 and Childhood Asthma study. FEV₁, forced expiratory volume in one second; FVC, forced vital
1210 capacity.

1211
1212

1213 **S3 Table. MeQTL analysis results and associations with FEV₁.** All CpG sites where DNA
1214 methylation levels in NECs at age 11 in URECA were associated with rs10220464 at FDR<0.05
1215 are shown with their corresponding associations with FEV₁. The FDR-adjusted P-values (FDR
1216 Q) correspond to a 5% false-discovery rate. FDR, false discovery rate; 95% CI, 95% confidence
1217 interval; FEV₁, forced expiratory volume in one second; URECA, Urban Environment and
1218 Childhood Asthma study.

1219
1220

1221 **S8 Fig. NicAlert Results by Study.** Distribution of urine cotinine levels, as measured using
1222 NicAlert immunochromatographic assays, which report results on a scale of 0-6 according to the
1223 labeled concentration ranges. Proportions were calculated relative to the number of samples
1224 with available NicAlert results. APIC, Asthma Phenotypes in the Inner City study; URECA,
1225 Urban Environment and Childhood Asthma study.

1226
1227

1228 **S9 Fig. DNA methylation at cg03306306 by smoking exposure.** DNA methylation levels at
1229 cg03306306 are shown by rs10220464 genotype in URECA participants with low and high
1230 smoking exposures in (A) NECs at age 11 and (B) PBMCs at age 7. FEV₁ (% predicted) are
1231 also shown by cg03306306 DNA methylation levels in URECA participants with low and high
1232 smoking exposures in (C) NECs at age 11 and (D) PBMCs at age 7. NECs, nasal epithelial
1233 cells; PBMCs, peripheral blood mononuclear cells; FEV₁, forced expiratory volume in one
1234 second; URECA, Urban Environment and Childhood Asthma study.

1235
1236

1237 **S10 Fig. Genotype associations with FEV₁ by smoking exposure.** FEV₁ (% predicted) are
1238 shown by rs10220464 genotype in APIC & URECA participants with low and high smoking
1239 exposures according to urine cotinine levels. FEV₁, forced expiratory volume in one second;
1240 APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood
1241 Asthma study.

1242
1243
1244 **S4 Table. rs10220464 eQTL analysis results.** Results of eQTL analyses in NECs and PBMCs
1245 with rs10220464 for all genes within 1 Mb in URECA. Gene expression was measured in counts
1246 per million mapped reads. The FDR-adjusted P-values (FDR Q) correspond to a 5% false-
1247 discovery rate. FDR, false discovery rate; 95% CI, 95% confidence interval; NECs, nasal
1248 epithelial cells; PBMCs, peripheral blood mononuclear cells; URECA, Urban Environment and
1249 Childhood Asthma study.

1250
1251
1252 **S11 Fig. PPP1R13B expression in NECs vs. smoking exposure, FEV₁.** PPP1R13B
1253 expression in NECs at age 11 was not associated with smoking exposure at age 10 (A) nor with
1254 FEV₁ (% predicted) at age 10 (B) in URECA. NECs, nasal epithelial cells; FEV₁, forced
1255 expiratory volume in one second; URECA, Urban Environment and Childhood Asthma.

1256
1257
1258 **S5 Table. Chromatin interactions with FEV₁-associated SNPs.** Bait and target fragments
1259 refer to mapped Hi-C restriction fragments on chr14 (hg38) for gene promoters and putative
1260 enhancers, respectively. FEV₁ SNPs refer to number of FEV₁-associated variants ($p < 1 \times 10^{-5}$)
1261 within 1kb of target fragment. SNPs, single nucleotide polymorphisms; FEV₁, forced expiratory
1262 volume in one second.

1263
1264
1265 **S6 Table. Age at used lung function measure in URECA.** URECA, Urban Environment and
1266 Childhood Asthma study; FEV₁, forced expiratory volume in one second; FVC, forced vital
1267 capacity.

1268
1269
1270 **S7 Table. Study samples.** APIC, Asthma Phenotypes in the Inner City study; URECA, Urban
1271 Environment and Childhood Asthma study; WGS, whole-genome sequencing; NECs, nasal
1272 epithelial cells; PBMCs, peripheral blood mononuclear cells.

1273
1274
1275 **S12 Fig. Data availability across APIC and URECA.** Data availability for measures used in
1276 this study are shown for all sequenced samples. Each row represents a pattern of available and
1277 missing data, with green squares indicating available data and grey squares indicating missing
1278 data. Total counts of available data points for each variable are listed across the top of the
1279 figure. Total counts for each data availability pattern are listed along the right.





1280
1281



1282 **S13 Fig. Transitions/transversions vs. quality/depth in WGS variant calls.** The
1283 transition/transversion ratio (TS/TV) is plotted against the variant call quality/depth metric (QD)
1284 across all WGS SNP calls in APIC & URECA. Sites with QD less than 4 or greater than 34 were
1285 removed from consideration in this study. SNPs, single nucleotide polymorphisms; WGS, whole-
1286 genome sequencing; APIC, Asthma Phenotypes in the Inner City study; URECA, Urban
1287 Environment and Childhood Asthma study.

1288
1289
1290 **S14 Fig. Intercorrelation of Mendelian randomization candidate instrument SNPs in**
1291 **URECA.** Instrumental variables were chosen from a set of candidate SNPs that were at least
1292 nominally associated with cg03306306 methylation with $p < 0.15$. The correlation values between
1293 these SNPs are shown, clustered using Ward's method. The four SNPs used for the instrument
1294 are highlighted. URECA, Urban Environment and Childhood Asthma.


1295
1296
1297 **S8 Table. Additional phenotypic, socioeconomic, and environmental data.** Additional
1298 variables examined for potential confounding in mediation analyses for APIC & URECA. APIC,
1299 Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma
1300 study.


1301
1302
1303 **S15 Fig. Intercorrelation of phenotypes and environmental variables in APIC & URECA.**
1304 The correlations are shown between FEV_1 (% predicted), smoking exposure (NicAlert), the
1305 primary the lead FEV_1 SNP rs10220464, DNA methylation at cg03306306, 11 environmental
1306 exposures, and 2 socioeconomic indicators, clustered using Ward's method. APIC, Asthma
1307 Phenotypes in the Inner City study; exp., exposure; URECA, Urban Environment and Childhood
1308 Asthma.







$-\log_{10}(p\text{-value})$








NECs






PBMCs




cg03306306 methylation









S1 Table. Post-QC sequencing call concordance between replicates.

Variant Type	Variants (mean)	Call concordance
All Variants	4,284,228	0.9985
SNPs	3,793,694	0.9997
Common SNPs (MAF > 0.05)	3,244,661	0.9997
Low Frequency SNPs (0.01 > MAF ≤ 0.05)	383,918	0.9995
Rare SNPs (MAF ≤ 0.01)	165,115	0.9995
InDels	490,534	0.9892
Common InDels (MAF > 0.05)	428,621	0.9896
Low Frequency InDels (0.01 > MAF ≤ 0.05)	39,572	0.9845
Rare InDels (MAF ≤ 0.01)	22,340	0.9911

Variant call concordance between three pairs of replicate samples, by variant type and cohort allele frequency. SNPs, single nucleotide polymorphisms; MAF, minor allele frequency; InDels, insertions and deletions.

S2 Table. FEV₁-associated variants in chr14q32.33

Pos	rsID	N	Ref	Alt	MAF	Beta	SE	P	Type	Gene
103936818	rs10220464	896	A	G	0.30	-0.311	0.052	2.42 x10⁻⁹	intronic	TDRD9
103926863	rs11850186	896	G	A	0.29	-0.307	0.052	5.34 x10 ⁻⁹	intergenic	ATP5MPL; TDRD9
103934654	rs4906387	896	C	T	0.29	-0.305	0.052	6.20 x10 ⁻⁹	intronic	TDRD9
103935736	rs9285602	896	C	T	0.29	-0.305	0.052	6.20 x10 ⁻⁹	intronic	TDRD9
103937635	rs9324069	896	G	A	0.29	-0.305	0.052	6.20 x10 ⁻⁹	intronic	TDRD9
103942966	.	896	GA	G	0.29	-0.305	0.052	6.20 x10 ⁻⁹	intronic	TDRD9
103960917	rs4900604	896	G	A	0.29	-0.305	0.052	6.20 x10 ⁻⁹	intronic	TDRD9
103963565	rs28574832	896	G	T	0.29	-0.305	0.052	6.20 x10 ⁻⁹	intronic	TDRD9
103967867	rs4900605	896	G	T	0.29	-0.305	0.052	6.20 x10 ⁻⁹	intronic	TDRD9
103997188	rs72712900	896	G	A	0.29	-0.304	0.052	6.51 x10 ⁻⁹	intronic	TDRD9
103984806	rs11847797	896	G	A	0.29	-0.303	0.052	7.73 x10 ⁻⁹	intronic	TDRD9
103980079	rs58289480	896	A	G	0.29	-0.303	0.052	8.28 x10 ⁻⁹	intronic	TDRD9
103985095	rs4906396	896	A	C	0.29	-0.303	0.052	8.28 x10 ⁻⁹	intronic	TDRD9
103953683	rs72712884	896	C	G	0.29	-0.303	0.052	8.28 x10 ⁻⁹	intronic	TDRD9
104046654	rs143594477	896	C	CT	0.29	-0.302	0.052	9.12 x10 ⁻⁹	intronic	TDRD9
104028226	rs10137997	896	T	C	0.29	-0.301	0.052	9.73 x10 ⁻⁹	intronic	TDRD9
104034493	rs9944163	896	G	T	0.29	-0.301	0.052	9.73 x10 ⁻⁹	intronic	TDRD9
104069368	rs72714937	896	C	T	0.29	-0.302	0.052	9.80 x10 ⁻⁹	intergenic	TDRD9; ASPG
104059833	rs11160785	896	T	A	0.29	-0.300	0.052	1.03 x10 ⁻⁸	intergenic	TDRD9; ASPG
103934222	rs28461376	896	A	G	0.29	-0.301	0.052	1.06 x10 ⁻⁸	intronic	TDRD9
103963484	.	896	TC	T	0.29	-0.301	0.052	1.06 x10 ⁻⁸	intronic	TDRD9
104037291	rs4906408	896	G	T	0.29	-0.299	0.052	1.14 x10 ⁻⁸	intronic	TDRD9
104030861	rs10135338	896	G	A	0.29	-0.299	0.052	1.18 x10 ⁻⁸	intronic	TDRD9
104035861	rs10134394	896	G	A	0.29	-0.299	0.052	1.18 x10 ⁻⁸	intronic	TDRD9
104036696	rs11160780	896	G	A	0.29	-0.299	0.052	1.18 x10 ⁻⁸	intronic	TDRD9
104037342	rs4900608	896	G	A	0.29	-0.299	0.052	1.18 x10 ⁻⁸	intronic	TDRD9
104038178	rs4906409	896	T	C	0.29	-0.299	0.052	1.18 x10 ⁻⁸	intronic	TDRD9
104039412	rs10144682	896	G	A	0.29	-0.299	0.052	1.18 x10 ⁻⁸	intronic	TDRD9
104012687	rs11851441	896	A	G	0.29	-0.299	0.052	1.23 x10 ⁻⁸	intronic	TDRD9
104031206	rs10135507	896	C	T	0.29	-0.298	0.052	1.25 x10 ⁻⁸	exonic	TDRD9
103998027	rs55938939	896	G	A	0.29	-0.299	0.052	1.26 x10 ⁻⁸	intronic	TDRD9
104048481	rs61244535	896	C	G	0.29	-0.299	0.052	1.29 x10 ⁻⁸	intronic	TDRD9
104051127	rs28644198	896	C	A	0.29	-0.299	0.052	1.29 x10 ⁻⁸	intronic	TDRD9
104054541	rs28377615	896	G	A	0.29	-0.299	0.052	1.29 x10 ⁻⁸	intergenic	TDRD9; ASPG
103997438	rs4906397	896	C	T	0.29	-0.298	0.052	1.31 x10 ⁻⁸	intronic	TDRD9
103999081	rs4906399	896	C	T	0.29	-0.298	0.052	1.31 x10 ⁻⁸	intronic	TDRD9
104005628	rs12147936	896	C	T	0.29	-0.298	0.052	1.31 x10 ⁻⁸	intronic	TDRD9
104010259	rs145867870	896	C	CT	0.29	-0.298	0.052	1.31 x10 ⁻⁸	intronic	TDRD9
104013496	rs11851723	896	C	T	0.29	-0.298	0.052	1.31 x10 ⁻⁸	intronic	TDRD9
104014746	rs11160779	896	T	C	0.29	-0.298	0.052	1.31 x10 ⁻⁸	exonic	TDRD9
104016537	rs72714909	896	C	A	0.29	-0.298	0.052	1.31 x10 ⁻⁸	intronic	TDRD9
103986068	rs10143030	896	C	G	0.29	-0.300	0.052	1.41 x10 ⁻⁸	intronic	TDRD9
103986303	rs10143389	896	G	A	0.29	-0.300	0.052	1.41 x10 ⁻⁸	exonic	TDRD9
103986825	rs61248168	896	T	A	0.29	-0.300	0.052	1.41 x10 ⁻⁸	intronic	TDRD9
103990858	rs1957518	896	G	A	0.29	-0.300	0.052	1.41 x10 ⁻⁸	intronic	TDRD9
104072329	rs111576189	896	G	A	0.29	-0.298	0.052	1.54 x10 ⁻⁸	intergenic	TDRD9; ASPG
104011541	rs28522352	896	T	A	0.29	-0.296	0.052	1.79 x10 ⁻⁸	intronic	TDRD9
104003975	rs8010286	896	T	C	0.29	-0.293	0.052	2.06 x10 ⁻⁸	intronic	TDRD9
104004349	rs28391043	896	G	A	0.29	-0.294	0.052	2.22 x10 ⁻⁸	intronic	TDRD9
104027784	rs28725314	896	C	T	0.29	-0.290	0.052	2.96 x10 ⁻⁸	intronic	TDRD9
103970594	rs11851097	896	C	T	0.36	-0.267	0.048	3.28 x10 ⁻⁸	exonic	TDRD9

Pos	rsID	N	Ref	Alt	MAF	Beta	SE	P	Type	Gene
103987132	rs200735321	880	A	G	0.26	-0.311	0.057	6.98 x10 ⁻⁸	intronic	<i>TDRD9</i>
104067149	rs10782497	896	T	C	0.39	-0.265	0.049	1.08 x10 ⁻⁷	intergenic	<i>TDRD9</i> ; <i>ASPG</i>
104019632	rs74089113	896	G	C	0.44	-0.246	0.046	1.25 x10 ⁻⁷	intronic	<i>TDRD9</i>
104071795	rs35775205	896	A	G	0.37	-0.264	0.050	1.72 x10 ⁻⁷	intergenic	<i>TDRD9</i> ; <i>ASPG</i>
104038358	rs877009	896	T	C	0.43	-0.240	0.046	3.06 x10 ⁻⁷	intronic	<i>TDRD9</i>
104007407	rs12100528	896	G	A	0.43	-0.240	0.047	3.32 x10 ⁻⁷	intronic	<i>TDRD9</i>
104016337	rs7158223	896	G	T	0.42	-0.238	0.046	3.83 x10 ⁻⁷	intronic	<i>TDRD9</i>
103947548	rs7144813	896	G	C	0.35	-0.244	0.049	8.48 x10 ⁻⁷	intronic	<i>TDRD9</i>
103937851	rs10141985	896	G	A	0.34	-0.242	0.050	1.53 x10 ⁻⁶	intronic	<i>TDRD9</i>
103939314	rs7148877	896	A	G	0.34	-0.241	0.050	1.73 x10 ⁻⁶	intronic	<i>TDRD9</i>
103945800	rs12147460	896	T	G	0.34	-0.241	0.050	1.73 x10 ⁻⁶	intronic	<i>TDRD9</i>
104032500	rs9944058	896	C	T	0.42	-0.235	0.049	2.22 x10 ⁻⁶	intronic	<i>TDRD9</i>
103981884	rs4906395	896	T	C	0.42	-0.220	0.047	2.71 x10 ⁻⁶	intronic	<i>TDRD9</i>
103958246	rs10149734	896	A	C	0.41	-0.221	0.047	3.04 x10 ⁻⁶	intronic	<i>TDRD9</i>
103962412	rs72712889	896	T	C	0.41	-0.221	0.047	3.04 x10 ⁻⁶	intronic	<i>TDRD9</i>
103967964	rs4906392	896	T	C	0.41	-0.221	0.047	3.04 x10 ⁻⁶	intronic	<i>TDRD9</i>
103995217	rs10132153	896	C	A	0.41	-0.220	0.047	3.16 x10 ⁻⁶	intronic	<i>TDRD9</i>
104036896	rs7156122	896	G	A	0.41	-0.217	0.046	3.28 x10 ⁻⁶	intronic	<i>TDRD9</i>
104014863	rs397949797	896	A	AT	0.41	-0.216	0.046	3.75 x10 ⁻⁶	intronic	<i>TDRD9</i>
103979872	rs8022833	896	A	G	0.41	-0.219	0.047	3.87 x10 ⁻⁶	intronic	<i>TDRD9</i>
103981060	rs1957517	896	A	G	0.41	-0.219	0.047	3.87 x10 ⁻⁶	intronic	<i>TDRD9</i>
103995157	rs10132127	896	C	G	0.41	-0.218	0.047	4.02 x10 ⁻⁶	intronic	<i>TDRD9</i>
104004783	rs9671921	896	A	G	0.49	-0.214	0.046	4.98 x10 ⁻⁶	intronic	<i>TDRD9</i>
104008697	rs4906401	896	A	G	0.41	-0.215	0.047	5.23 x10 ⁻⁶	intronic	<i>TDRD9</i>
104001342	rs61319604	896	C	T	0.41	-0.215	0.047	5.35 x10 ⁻⁶	intronic	<i>TDRD9</i>
104002208	rs72714904	896	T	C	0.41	-0.215	0.047	5.35 x10 ⁻⁶	intronic	<i>TDRD9</i>
104003206	rs10135296	896	G	T	0.41	-0.215	0.047	5.35 x10 ⁻⁶	intronic	<i>TDRD9</i>
104006916	rs4900607	896	A	G	0.49	-0.212	0.046	5.90 x10 ⁻⁶	intronic	<i>TDRD9</i>
104010388	rs4906402	896	G	A	0.41	-0.213	0.047	6.22 x10 ⁻⁶	intronic	<i>TDRD9</i>
104000834	rs7160557	896	G	A	0.48	-0.207	0.046	8.97 x10 ⁻⁶	intronic	<i>TDRD9</i>
104078948	rs4906415	896	G	A	0.19	-0.268	0.060	9.00 x10 ⁻⁶	intergenic	<i>TDRD9</i> ; <i>ASPG</i>

All variants in chr14q32.33 associated with FEV₁ (% predicted) with $p < 1 \times 10^{-5}$ (n=82) in GWAS of 896 participants from APIC & URECA. N, number of genotyped individuals. MAF, minor allele frequency; 95% CI, 95% confidence interval; SE, standard error; P, P-value (Wald); FEV₁, forced expiratory volume in one second; APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma study.

S3 Table. MeQTL analysis results and associations with FEV₁

CpG Site	Position (strand), hg38 (chr14)	rs10220464			FEV ₁	
		Beta [95% CI]	P	FDR Q	Beta [95% CI]	P
cg21567958	103909862 (-)	0.10 [0.05, 0.14]	1.79 x10 ⁻⁵	0.01	-1.5 [-8.8, 5.7]	0.68
cg12183467	103885907 (-)	0.10 [0.05, 0.14]	1.31 x10 ⁻⁴	0.04	5.3 [-1.5, 12.1]	0.13
cg16820107	103970549 (-)	0.08 [0.04, 0.12]	1.62 x10 ⁻⁴	0.04	-5.4 [-13.4, 2.5]	0.18
cg03306306	104001397 (+)	0.07 [0.03, 0.11]	2.28 x10⁻⁴	0.04	-11.5 [-20.3, -2.7]	0.01
cg17298714	103938355 (+)	0.14 [0.07, 0.21]	2.36x10 ⁻⁴	0.04	-4.1 [-8.7, 0.4]	0.07

All CpG sites where DNA methylation levels in NECs at age 11 in URECA were associated with rs10220464 at FDR<0.05 are shown with their corresponding associations with FEV₁. The FDR-adjusted P-values (FDR Q) correspond to a 5% false-discovery rate. FDR, false discovery rate; 95% CI, 95% confidence interval; FEV₁, forced expiratory volume in one second; URECA, Urban Environment and Childhood Asthma study.

S4 Table. rs10220464 eQTL analysis results

Gene	NECs			PBMcs	
	Beta [95% CI]	P	FDR Q	Beta [95% CI]	P
PPP1R13B	0.12 [0.06, 0.17]	1.26 x10⁻⁵	2.77 x10⁻⁴	0.01 [-0.08, 0.09]	0.87
<i>BAG5</i>	-0.06 [-0.02, -0.10]	0.0054	0.059	0.03 [-0.03, 0.08]	0.31
<i>ASPG</i>	0.12 [-0.02, 0.26]	0.089	0.48	NOT EXPRESSED	
<i>CKB</i>	-0.04 [0.01, -0.09]	0.10	0.48	0.13 [-0.03, 0.30]	0.12
<i>KLC1</i>	-0.04 [0.01, -0.08]	0.12	0.48	0.02 [-0.04, 0.07]	0.53
<i>TNFAIP2</i>	-0.05 [0.02, -0.12]	0.15	0.48	-0.11 [0.06, -0.28]	0.22
<i>MARK3</i>	-0.03 [0.01, -0.07]	0.15	0.48	-0.02 [0.02, -0.06]	0.40
<i>C14orf2</i>	0.01 [-0.01, 0.03]	0.23	0.61	-0.03 [0.03, -0.09]	0.35
<i>XRCC3</i>	0.08 [-0.06, 0.22]	0.25	0.61	0.00 [0.06, -0.07]	0.92
<i>ZFYVE21</i>	0.02 [-0.01, 0.04]	0.28	0.61	-0.02 [0.03, -0.07]	0.49
<i>ADSSL1</i>	0.04 [-0.04, 0.11]	0.33	0.61	0.04 [-0.09, 0.17]	0.54
<i>PLD4</i>	0.07 [-0.07, 0.20]	0.33	0.61	0.07 [-0.12, 0.26]	0.47
<i>SIVA1</i>	-0.01 [0.01, -0.03]	0.36	0.61	0.01 [-0.06, 0.09]	0.77
<i>EXOC3L4</i>	-0.08 [0.14, -0.29]	0.47	0.69	NOT EXPRESSED	
<i>TRMT61A</i>	-0.02 [0.04, -0.09]	0.48	0.69	-0.04 [0.04, -0.12]	0.32
<i>CEP170B</i>	-0.02 [0.05, -0.09]	0.51	0.69	0.02 [-0.11, 0.14]	0.78
<i>APOPT1</i>	-0.02 [0.04, -0.08]	0.56	0.69	-0.03 [0.03, -0.09]	0.37
<i>EIF5</i>	-0.01 [0.02, -0.04]	0.60	0.69	-0.03 [0.05, -0.12]	0.44
<i>TDRD9</i>	-0.07 [0.21, -0.36]	0.60	0.69	0.01 [-0.23, 0.26]	0.91
<i>ZBTB42</i>	-0.02 [0.05, -0.08]	0.63	0.69	-0.09 [0.01, -0.19]	0.089
<i>INF2</i>	-0.01 [0.08, -0.10]	0.84	0.85	0.04 [-0.06, 0.13]	0.45
<i>AKT1</i>	0.00 [0.03, -0.03]	0.85	0.85	-0.02 [0.04, -0.08]	0.57
<i>AL049840.1</i>	NOT EXPRESSED			0.00 [0.08, -0.09]	0.93
<i>AL049840.4</i>	NOT EXPRESSED			0.01 [-0.05, 0.08]	0.65
<i>AL049840.5</i>	NOT EXPRESSED			0.02 [-0.08, 0.13]	0.68
<i>AL133367.1</i>	NOT EXPRESSED			0.09 [-0.02, 0.20]	0.12
<i>LINC00638</i>	NOT EXPRESSED			0.03 [-0.11, 0.18]	0.66

Results of eQTL analyses in NECs and PBMcs with rs10220464 for all genes within 1 Mb in URECA. Gene expression was measured in counts per million mapped reads. The FDR-adjusted P-values (FDR Q) correspond to a 5% false-discovery rate. FDR, false discovery rate; 95% CI, 95% confidence interval; NECs, nasal epithelial cells; PBMcs, peripheral blood mononuclear cells; URECA, Urban Environment and Childhood Asthma study.

S5 Table. Chromatin interactions with FEV₁-associated SNPs

Promoter	Bait Fragment	Target Fragment	Strand	Distance	FEV ₁ SNPs	CHiCAGO Score
PPP1R13B	103845355-103845955	104003512-104004312	-	157557	4	9.38
<i>CDCA4</i>	105020395-105021827	104010864-104011532	-	1008863	3	7.65
PPP1R13B	103845355-103845955	104004616-104004922	-	158661	4	7.16
<i>ZFYVE21</i>	103716777-103717467	103948470-103949743	+	231003	1	6.57
<i>ZFYVE21</i>	103716777-103717467	103933835-103934479	+	216368	2	6.49
<i>C14orf79</i>	104985639-104987255	103935625-103936182	+	1049457	3	6.10
<i>MARK3</i>	103385080-103385712	103937160-103938502	+	551448	4	5.89
<i>ZFYVE21</i>	103715624-103716777	103981359-103981909	+	264582	2	5.89
<i>PLD4</i>	104927266-104927937	103963380-103964018	+	963248	3	5.69
<i>ZFYVE21</i>	103715624-103716777	103933397-103933835	+	216620	2	5.62
<i>ADSSL1</i>	104720007-104724747	104017055-104017482	+	702525	2	5.52
<i>APOPT1</i>	103562490-103563614	103999031-103999343	+	435417	1	5.48
<i>CKB</i>	103521551-103522109	103997308-103998030	-	475199	3	5.26
<i>MARK3</i>	103385881-103386341	103958731-103959336	+	572390	1	5.19
PPP1R13B	103845355-103845955	104036454-104037811	-	190499	7	5.00

Bait and target fragments refer to mapped Hi-C restriction fragments on chr14 (hg38) for gene promoters and putative enhancers, respectively. FEV₁ SNPs refer to number of FEV₁-associated variants ($p < 1 \times 10^{-5}$) within 1kb of target fragment. SNPs, single nucleotide polymorphisms; FEV₁, forced expiratory volume in one second.

S6 Table. Age at used lung function measure in URECA

Age (years)	Count	
	FEV ₁	FEV ₁ /FVC
10	382	372
9	26	30
8	10	11
7	8	5
6	6	10
5	9	10

URECA, Urban Environment and Childhood Asthma study; FEV₁, forced expiratory volume in one second; FVC, forced vital capacity.

S7 Table. Study samples



Cohort	Sample	Cell Type	Age Collected	N
APIC	WGS	-	-	508
URECA	WGS	-	-	527
URECA	DNA Methylation	NECs	11	286
URECA	DNA Methylation	PBMCs	7	169
URECA	RNA-Seq	NECs	11	324
URECA	RNA-Seq	PBMCs	2	132



APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma study; WGS, whole-genome sequencing; NECs, nasal epithelial cells; PBMCs, peripheral blood mononuclear cells.



S8 Table. Additional phenotypic, socioeconomic, and environmental data


Variable	Description	Units	N
Socioeconomic factors			
Income<\$15K	Family yearly income <\$15,000	yes/no	1018
Caretaker education	Caretaker completed high school	yes/no	1031
Environmental exposures			
Gas stove at home	Gas stove in home	yes/no	982
Dampness at home	Water problems in home	yes/no	981
AC at home	AC unit in child's bedroom	yes/no	982
Airvents at home	Forced air for heat in home	yes/no	983
Rodent allergen exposure	Mus m 1 (mouse) bedroom allergen levels	log($\mu\text{g/g}$)	847
Roach allergen exposure	Bla g 1 (German cockroach) bedroom allergen levels	log($\mu\text{g/g}$)	850
Dust mite allergen exposure	Combined Der f 1 (<i>Dermatophagoides farina</i>) and Der p 1 (<i>Dermatophagoides pteronyssinus</i>) bedroom allergen levels	log($\mu\text{g/g}$)	756
Dog allergen exposure	Can f 1 bedroom allergen levels	log($\mu\text{g/g}$)	839
Cat allergen exposure	Fel d 1 bedroom allergen levels	log($\mu\text{g/g}$)	839
NO ₂ at home	Indoor nitrogen dioxide levels	log(ppb)	900
Caloric intake	Total caloric intake	log(calories/day)	787





Additional variables examined for potential confounding in mediation analyses for APIC & URECA. APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma study.


A**B**



AFEV₁ (% predicted)**B**FEV₁/FVC (Z-score)




A**FEV₁ (% Predicted)****B****FEV₁/FVC**



NicAlert Results by Study

APIC

URECA





NECs

PBMCs

A







Low cotinine
≤30ng/ml

High cotinine
>30ng/ml


**B**

Low cotinine
≤30ng/ml


High cotinine
>30ng/ml


**C****D**

Low cotinine $\leq 30\text{ng/ml}$



High cotinine $> 30\text{ng/ml}$



A**B**